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1. Summary
1 Summary
Focal epilepsies represent multifactorial disorders. Hence, pathogenetic factors, episod-
ically shifting the brain over a virtual threshold to the emergence of seizures, are
individually neither necessary nor sufficient. In recent years, several SNPs located in
potential promoter regions of related genes have been detected in patients suffering
from episodic CNS disorders. Transiently altered expression of corresponding genes
therefore constitutes a potential pathogenetic aspect for the manifestation of episodic
symptoms. The availability of biopsy tissue from epilepsy surgery of pharmacoresistant
TLE patients provides a unique prerequisite in order to study the potential impact of
gene promoter variants on transcription as well as the correlation of gene expression
involved in neurotransmission and immune responses corresponding to stratification of
patients according to clinical parameters.
The focus of this study was to gain further insights on the potential impact of SNPs
located in transcriptional regulatory regions to modulate the expression of respective
genes coding for neurotransmitter receptors including serotonin receptors and genes
related to inhibition and neurotransmission, i.e. genes involved in γ-aminobutyric
acid (GABA)-ergic homeostasis, on the basis of human surgical hippocampal brain
tissue. By using real-time RT-PCR we found differential mRNA expression levels of
relevant genes corresponding to the presence of respective SNP genotypes. To unravel
the mechanisms of altered promoter control via regulatory SNP influence or aberrant
transcription factor effects, we performed comprehensive bioinformatic analysis in or-
der to identify binding sites for transcription factors and their potential modification
by promoter SNPs. We observed that respective promoter SNPs affect transcription
factor binding. Additionally, we showed an allele-dependent regulation of gene expres-
sion after exposure to relevant transcription factors using luciferase reporter asays.
Furthermore, given the potential impact of seizure frequency on gene expression, we
analyzed the correlation of gene expression levels in surgical hippocampi from TLE
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patients with clinical or functional parameters. We found a significant correlation of
expression of distinct mediator genes of inflammation to seizure frequency in human
surgical brain tissue of pharmacoresistant TLE patients.
Our data indicate novel insights in the relevance of dynamic expression of genes related
to neurotransmission and inflammation based on human brain tissue of TLE patients
not responding to antiepileptic drugs.
2
2. Introduction
2 Introduction
2.1 Epilepsy
Epilepsies belong to the most common neurological disorders in humans and are char-
acterized by spontaneous appearance of two or more unprovoked seizures due to recur-
rent abnormal excessive or synchronous neuronal activity in the brain (Fisher et al.,
2005). About 10% of the population are exposed to one seizure during their life-
time (Hauser et al., 1990). Epileptic seizures generate either focal or generalized
paroxysomal changes, which are induced by excessive, abnormal or synchronous neu-
ronal activity in the brain (Hauser and Kurland, 1975; Dichter, 1994; Sanabria et al.,
2001; Fisher et al., 2005; Fritschy, 2008; Banerjee et al., 2009). In generalized epilepsy,
seizures are not restricted to a particular brain region. In focal epilepsy, the abnormal
neuronal activity onset is restricted to one defined brain region, the so called epileptic
focus.
A proportion of 0.5 to 1% of the population suffer from chronic epilepsy (Hauser et al.,
1996; Elger, 2002). Epilepsies can be divided in symptomatic and idiopathic syn-
dromes. The genetically defined idiopathic epilepsies manifest without structural or
other predisposing cause. Both focal and generalized forms of epilepsy can be caused
by genetic defects, e.g. in genes coding for voltage gated sodium, potassium channels or
GABAA receptor chloride channels, called channelopathies (Heron et al., 2007). The
most common form constitutes the idiopathic generalized epilepsy (IGE) comprising
juvenile myoclonic epilepsy (JME) and childhood absence epilepsy (CAE). Juvenile
myoclonic epilepsy (JME) is usually featured by first seizure onset between the ages of
12 and 18 and seizure episodes occurring after a sleep period. JME is characterized by
myoclonic, generalized tonic-clonic seizures and, infrequently, absence seizures (Genton
and Gelisse, 2001). Childhood absence epilepsy (CAE) constitutes 10 - 17% of all cases
of childhood-onset epilepsy and typically begins at 4 - 10 years with a peak at age
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between 5 - 7 years (Berg et al., 2000). These patients have frequent absence seizures.
Symptomatic epilepsies are caused by acquired or native structural or metabolic de-
fects of the brain, e.g. perinatal or postnatal trauma, infections of the central nervous
system (CNS) or cerebrovascular lesions. These forms of epilepsies mainly have a fo-
cal origin due to e.g. tumors, stroke or hippocampal sclerosis. The latter is major
pathology in temporal lobe epilepsy (TLE).
2.1.1 Temporal Lobe Epilepsy
Temporal lobe epilepsy (TLE) is one specific form of epilepsy characterized by focal
seizures, which can secondarily generalize. TLE represents the most common form of
acquired epilepsy in humans and affects approximately 70% of all epilepsy patients
(Engel, 1996a; Sirven, 2002). In TLE, the hippocampus often shows the pathology
of Ammon’s horn (or hippocampal) sclerosis (AHS). About 35% of the TLE patients
have focal lesions such as benign glial and glioneuronal tumors as well as cortical mal-
formations (Blu¨mcke et al., 1996; Thom, 2004). 5 - 20% of epilepsy patients manifest
a structural or focal lesion together with AHS, which is indicated as a ’dual pathology’
of epilepsy (Wieser, 2004). With regard to TLE etiology, febrile seizures in early child-
hood often correlate to the development of TLE. However, also brain insults, stroke,
infections of the CNS as well as malformations in the cortical development or brain
tumors can act as initial event of epileptogenesis (Brooks-Kayal et al., 2009; Pitkanen
et al., 2009; Rakhade and Jensen, 2009).
2.1.1.1 Ammon’s horn sclerosis
The hippocampal formation is localized in the temporal lobe and belongs to the limbic
system. The hippocampus is responsible for consolidation of short-term and long-term
memory information, emotions and spatial navigation (Scoville and Milner, 1957; Nunn
et al., 1999). The hippocampal formation consists of the dentate gyrus, the subiculum
and the cornu Ammonis (Ammon’s horn), which itself comprises the hippocampal
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regions CA1 to CA4. In the case of TLE patients, the pattern of AHS as most com-
mon neuropathological finding is diagnosed in about 60% of epilepsy-surgical resections
(Blu¨mcke et al., 2002; Majores et al., 2007). The segmental neuronal cell loss in the
hippocampal formation is defined according to its distribution pattern in four different
types relevant to the Blu¨mcke classification (Blu¨mcke et al., 2007). The classical pat-
tern of AHS is characterized by a severe nerve cell loss in CA1 and a moderate loss in
CA2, CA3 and CA4 (type 1A according to Blu¨mcke). A massive neuronal cell loss in
all hippocampal regions is classified as type 1B according to Blu¨mcke. Type 2 shows a
striking neuronal cell loss in CA1 (CA1 sclerosis), whereas in the so called endfolium
sclerosis (type 3 according to Blu¨mcke) neuronal cells are mostly preserved in CA1
and a massive cell loss is detectable in CA2, CA3 and CA4. The degree of severity of
the hippocampal sclerosis is significantly influenced by several factors such as duration
of epilepsy, the age of patients at seizure onset and the occurrence of febrile seizures
in early childhood (Davies et al., 1996; Blu¨mcke et al., 1999; Janszky et al., 2005; von
Lehe et al., 2006).
2.1.2 Pharmacoresistant epilepsies and epilepsy surgery
In many patients, seizures in epilepsy are well treatable with existing antiepileptic
drugs (AEDs). However, in a significant number of patients no response to any of
these several diverse acting drugs occurs. These patients have to be designated as
pharmacoresistant, if the treatment with two ore more AEDs does not lead to seizure
control. In particular, TLE patients are known to frequently generate pharmacoresis-
tance (30%) (Engel, 1996b; Regesta and Tanganelli, 1999).
To date, two main concepts are established for explaining the molecular cause of phar-
macoresistance: first, aberrant function and upregulation of multidrug transporters at
the blood-brain barrier (BBB) leads to a decreased and therefore insufficient concen-
tration of AEDs in the brain parenchyma (’transporter hypothesis’; Kwan and Brodie
2005). Secondary, the so called ’target hypothesis’ is based on potential alterations of
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AED targets, such as neurotransmitter receptors or voltage-gated ion channels (Heine-
mann et al., 2006; Remy and Beck, 2006).
In pharmacoresistant patients, the required alternative therapy is given by the oppor-
tunity of surgical resection of the epileptic focus. Electroencephalogram (EEG) video
monitoring, neuropsychological evaluation and invasive electrophysiological methods
are used for mapping of the epileptic focus. The removal of the epileptic focus pro-
vides remarkable prospects for the TLE patients. In 70% of the cases, patients become
seizure free, for further 20% of the patients epilepsy surgery results in considerable
seizure reduction (< 90%) and only 10% of the patients do not benefit from epilepsy
surgery (Engel et al., 1993).
Epilepsy surgery provides the opportunity to obtain fresh human epileptic brain tissue
for molecular experiments.
2.2 Inflammation
Naturally, inflammation is part of the immune system defense against injury and dis-
ease. Chronic brain inflammation includes activation of microglia, astrocytes, endothe-
lial cells of the BBB and peripheral immune cells as well as accompanied production of
inflammatory mediators such as in the epileptic syndrome of Rasmussen’s encephali-
tis (Rasmussen et al., 1958). Mediators are produced from tissue-resident or blood-
circulating immunocompetent cells during a dynamic process and are involved in acti-
vation of the innate and adaptive immunity (Vezzani et al., 2011).
Increasing evidence indicates that inflammation plays a prominent role in the patho-
physiology of a number of human epilepsies and convulsive disorders (Wirrell et al.,
2005; Bauer et al., 2009). Furthermore, numerous studies suggest that inflammatory
processes in the CNS are either caused by or contribute to epileptogenesis (Vezzani
et al., 2002; Vezzani and Granata, 2005). This is emphasized by the detection of
inflammatory mediators, for example interleukins, interferons, chemokines or tumor
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necrosis factors, in surgical brain tissue from patients with refractory epilepsies (Vez-
zani and Granata, 2005; Choi et al., 2009). Experimental evidence indicates that seizure
activity can lead to initiation of brain inflammation (Vezzani and Granata, 2005; Ri-
azi et al., 2010). Additionally, as previously reported, a prolonged proinflammatory
state in the CNS may contribute to seizure predisposition and occurrence. This in
turn is associated with changes in neuronal excitability and enhanced seizure-induced
neuropathology (Ravizza et al., 2008; Vezzani and Granata, 2005). Furthermore, this
aspect is highlighted by previously reported alterations in seizure susceptibility in
genetically modified mice with impaired inflammatory signaling (Sarro et al., 2004;
Balosso et al., 2005).
2.3 Promoter characteristics and detection
The typical structure of an eukaryotic gene promoter consists of regulatory sequences
(Figure 1) such as core elements and several enhancer or silencer elements distributed
at various distances from the transcription start site (TSS) of the gene (Wasserman
and Sandelin, 2004; Halfon, 2006). The core promoter is often located approximately
100bp upstream of the first exon and comprises the initiator element (INR) and an AT-
rich site located 25 - 30bp upstream of the TSS, known as TATA-box. The proximal
promoter region harbors binding sites for special functional proteins that control gene
transcription rates. Especially in eukaryotes, regulatory elements such as enhancers,
repressor elements and silencers which influence the transcription independent of their
orientation, are often located up to 85 kb from the TSS (distal promoter) (Blackwood
and Kadonaga, 1998; Lin et al., 2007; Kuttippurathu et al., 2011).
Repressors interact with the Deoxyribonucleic acid (DNA) sequence in order to affect
the transcription of a corresponding gene. Repressors can act in the classical fashion
in an orientation- and position-dependent manner (Ogbourne and Antalis, 1998) or by
interfering with the binding of an activator (Hanna-Rose and Hansen, 1996). Proximal
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as well as distal regulatory regions are often arranged in clusters, so called cis-regulatory
modules, which cover similar signals (Halfon, 2006).
Figure 1: Characteristics of the eukaryotic promoter region. The general promoter in eukaryotes
consists of the core, the proximal and the distal promoter region in upstream order relative to the
transcription start site (TSS). These regions are characterized by distinct sequence patterns. The core
promoter contains several closely located TSSs with different rates of initiation grouped as initiator
element (INR), an AT-rich site called TATA box sufficient for directing transcription initiation by
a basal transcription complex. General transcription factors are known to bind to the CAAT box.
Binding sites for specific transcription factors are located in the proximal promoter region to control
gene transcription rates. Up to 85kb upstream of the TSS in the distal promoter region, regulatory
elements can influence the gene transcription by e.g. interfering with the transcription initiation
complex. In some cases downstream promoter elements (DPEs) are positioned downstream of the
TSS (modified from Wasserman and Sandelin 2004).
Known gene promoter regions are generally available in various databases. The Eu-
karyotic Promoter Database (EPD) comprises annotated non-redundant experimen-
tally identified eukaryotic promoters, whereas the Mammalian Promoter Database
(MPromDb) harbors annotated promoters identified from Chromatin Immunoprecipi-
tation Sequencing (ChIP-Seq) experiment results (Pe´rier et al., 2000; Sun et al., 2006).
Direct detection of promoters is also possible from genomic sequences. Multiple meth-
ods and algorithms have been developed in the past few years to identify promoter
regions. To localize the TSS, as one main characteristic of the gene promoter, the soft-
ware tool Eponine uses a neuronal network model based on position weight matrices
(PWMs) for the collection of positioned constraints (Down and Hubbard, 2002). Such
positional characteristics comprise a GC-rich region downstream of the potential TSS,
TATAAA motifs corresponding to the widely reported TATA box and additional two
GC-rich motifs flanking the identified TATA box.
In about 70% of human promoters, long stretches of GC-rich regions, so called CpG is-
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lands, are present and therefore denote a often relevant feature of the 5’-region of mam-
malian genes (Antequera, 2003). EMBOSS Cpgplot from the European Bioinformatics
Institute (EBI) at the European Molecular Biology Laboratory (EMBL) presents an
efficient tool to find such CpG islands associated with promoters (Rice et al., 2000).
As previously described, eukaryotic promoter regions have an abundance of TATA- as
well as CAAT-motifs. Therefore, combining both TATA and CAAT position weight
matrices to scan genomic upstream regions, constitute an intriguing option for the dis-
covery of promoter characteristics.
In summary, the combination of the results of multiple distinct promoter detection
methods may provide a useful approach in order to designate a potential promoter
region for a gene of interest.
2.3.1 Transcription factors and their binding sites
Gene transcription is mainly concerted by a large number of regulatory proteins. Gen-
erally, transcription factors (TFs) are classified according to their mechanistic, func-
tional or structural role. Ubiquitously expressed general transcription factors includ-
ing TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH represent a mechanistic class
of TFs. General TFs play a role in the formation of the preinitiation complex. As
second mechanistic class, specific transcription factors bind upstream of the TSS to
enhance or repress gene transcription (Conaway and Conaway, 1997; Torchia et al.,
1998; Maldonado et al., 1999; Na¨a¨r et al., 2001).
Based on the functional role, so called constitutive active nuclear factors with a tran-
scriptional activating function are present in the cell nucleus of all cells at all time.
This group comprises SP1, NF1, CCAAT and general transcription factors (Brivanlou
and Darnell, 2002). Conditionally active TFs depend on an external activation signal.
One subgroup is cell-type specific, i.e. it requires extracellular signals to be first gener-
ated and then enter the nucleus without further regulation by posttranslational signals.
So called signal-dependent TFs are developmentally limited or present in all cells in
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an inactive form until the activation by an intra- or extracellular signal (Brivanlou
and Darnell, 2002). Dependent on sequence similarity of their respective DNA-binding
motifs, TFs are also grouped in superclasses of basic domains, zinc-coordinating DNA-
binding domains, helix-turn-helix domains and beta-scaffold factors with minor groove
contacts (Stegmaier et al., 2004).
The function of TFs is reflected by the classical structure consisting of a DNA binding
domain responsible for the binding to the DNA sequence and a transcriptional activa-
tion domain. The activation domain mediates stimulatory or inhibitory effects on gene
transcription by interacting either in a direct fashion with specific components of the
basal transcriptional complex or indirectly with co-activators, which then interact with
the basal transcriptional complex (Latchman, 1997). Besides transcriptional activation
by activating TFs, repressing TFs may act as competitive binding proteins as well as
interaction partners of the activating TF to prevent the activity of its activation do-
main. Likewise, in order to inhibit the activating TF from binding to the target DNA
sequence, the repressing TF operate as direct DNA binding partner or by formation of
a non-DNA binding complex with the activating TF (Latchman, 1997).
In general, TFs interact with short (typically a length of 6 - 20 bases) cis-acting se-
quence stretches called transcription factor binding sites (TFBSs). It is known that
TFs interact in a sequence specific manner, due to the fact that not all nucleotides
of the TFBS actually form a bond with the TF and the degree of interaction differs
among each other. Furthermore, a single TF is not restricted to one binding motif
but has the ability to identify a subset of binding motifs featured by minimal sequence
differences. Considering the highly diverse and variable binding motifs for each TF,
their detection and characterization represents a challenge.
2.3.2 Prediction of transcription factor binding sites
The detection of TFBSs in the promoter region of a gene constitutes an initial step in
order to unravel regulatory mechanisms of gene regulation. Taking into account that
10
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binding motifs for one TF are often similar to each other but not necessarily identical,
the motif finding problem may be defined as:
”Given a set of sequences (promoter regions), detect overrepresented motifs that are
good candidates for being transcription factor binding sites” (Sinha and Tompa, 2003).
Most motif finding algorithms based on position weight matrices (PWMs), synonymous
with position specific scoring matrices (PSSMs), imitate position specific variations
such as quantitative preferences between the nucleotides at each position. Therefore,
multiple experimentally validated binding sites for one TF are aligned and a posi-
tion frequency matrix (PFM) is established that contains the frequency of observed
nucleotides at each position of the alignment. First, normalized values of the PFM
are converted to a log-scale using the formula (1) to finally provide a quantitative
description of the already known binding sites for the TF (Stormo, 2000).
PWMconversion : Wb,i = log2
p(b, i)
p(b)
(1)
where p(b) = background probability of base b; p(b, i) = corrected probability of base
b in position i; Wb,i = PWM value of base b in position i.
The resulting PWM assumes independence between the positions in the pattern (left-
most in Figure 2). By adding the relevant nucleotide PSSM values at each position,
a quantitative score for a potential sequence motif can be generated. This score is
proportional to the binding energy of the TF to the DNA (Berg and von Hippel, 1987;
Stormo, 2000). A graphical method to determine the consensus sequence as well as
the relative frequency of the bases and the information content at every position in a
binding site is given by a sequence logo (rightmost in Figure 2; Schneider and Stephens
1990). The sequence logo in Figure 2 showed an instantaneous visual overview of motif
characteristics taking the example of the TF Early growth response 3 (Egr-3).
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
A C G T
01 17.1 7.3 9.8 65.9
02 1.9 0.0 98.1 0.0
03 0.0 100.0 0.0 0.0
04 0.0 0.0 100.0 0.0
05 0.0 0.0 0.0 100.0
06 32.1 0.0 67.9 0.0
07 0.0 0.0 100.0 0.0
08 0.0 0.0 100.0 0.0
09 5.7 88.7 0.0 5.7
10 0.0 0.0 100.0 0.0
11 2.0 0.0 34.0 64.0

Figure 2: Representative position specific scoring matrix (PSSM) of Egr-3 with corresponding sequence
logo. On the left side, the PSSM is illustrated by a matrix with one row for each base and one column
for each position in the pattern. On the right side, the sequence logo is composed of a stack for
each position in the sequence. The sequence conservation at each position is indicated by the overall
height of the stack, while the depth of each single symbol within the stack is made proportional to
the frequency of each nucleic acid at that position.
One traditional public data source for PSSMs is named TRANScription FACtor database
(TRANSFAC) sponsored by BIOBASE. This database integrates data of eukaryotic
transcription factors, their experimentally-proven binding sites as well as consensus
binding sequences (Wingender et al., 1996; Wingender, 2008).
2.4 Single nucleotide polymorphism
The comparison of two randomly selected human genomes reveals up to 99.9% se-
quence identity. The remaining 0.1% consist of sequence variations (Shastry, 2002).
These sequence variations comprise besides tandem repeats, such as mini- and micro-
satellites, large and small segmental deletions, insertions or duplications, so called
single nucleotide polymorphisms (SNPs) (Chorley et al., 2008). SNPs are single base
substitutions in genomic DNA among different individuals in some populations. SNPs
constitute about 90% of all known sequence variations and are depicted to be highly
abundant, stable and distributed throughout the genome by occurring at a frequency
of approximately 1 in 1000 base pairs (Brookes, 1999). The distribution in the entire
12
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genome ranges over coding regions of genes, non-coding regions and intergenic regions.
Synonymous SNPs do not alter the encoded amino acid sequence and do not undergo
natural selection (Kimura, 1983). Otherwise, non-synonymous SNPs change the pro-
tein sequence and may be subjects to natural selection.
SNPs are not exclusively present in coding regions but also in regulatory regions such
as promoters, enhancers and silencers. They affect gene splicing, messenger RNA
(mRNA) degradation, transcription factor binding or promoter activity (Lohrer and
Tangen, 2000). Such SNPs are often designated as regulatory SNPs (rSNPs) (Knight,
2005; Wang et al., 2005). Generally, a rSNP occurring in a potential binding site for a
TF does neither influence the binding affinity nor alter the corresponding gene expres-
sion. However, in some cases the SNP leads to an increase or decrease of the interaction
potency of TF and DNA sequence and therefore to allele-specific gene expression. In
contrast, the complete elimination of the natural binding site or the generation of a
recent binding site due to the occurrence of a SNP appears quite rarely (Figure 3).
Considering the up-to-date huge amount of about 62676337 annotated human SNPs
(dbSNP build 138 date April 25, 2013) in the dSNP database of the National Center
for Biotechnology Information (NCBI), the importance of SNPs for genetic analyses
becomes more and more explicit (Sherry et al., 2001).
13
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Figure 3: Alternative influences of SNP on TFBS. The rSNP (red bar) is located in a TFBS (grey)
and potentially alters the binding of a TF (green) to the TFBS and further gene expression. From left
to right: SNP has neither effect on the binding affinity nor alter the corresponding gene expression.
Sometimes SNPs increase or rather decrease the binding to TFBS and therefore leads to allele-specific
gene expression. In rare cases, the natural binding site of TF is destroyed or a recent binding site is
generated (modified from Chorley et al. 2008).
2.5 Integrated investigation of expression analysis and genome-
wide association studies
The transcript level of a gene can be influenced by DNA sequence variations such as
SNPs, structural variations of large DNA stretches (copy number variants, CNVs),
insertions and deletions or short tandem repeats and by epigenetic modifications such
as methylation of CpG-residues or post-translational modifications of histones (Eck-
hardt et al., 2006; Shimada et al., 2009). As mentioned before, SNPs may functionally
influence multifactorial diseases, such as epilepsy, by directly altering the abundance
of a gene transcript. As a consequence, transcript alterations may be considered as a
quantitative trait. Regulatory regions that control levels of gene expression are mapped
as expression quantitative trait loci (eQTL) (Schadt et al., 2003; Morley et al., 2004).
Cis-acting eQTLs mapped proximal to the gene and cover SNPs within 100 kb up- and
14
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downstream of their gene-of-origin. Conversely, eQTLs mapped at long distances from
their gene-of-origin are more numerous and referred to as trans-eQTLs (Michaelson
et al., 2009).
Analysis of eQTLs provides considerable potential for examination of transcriptional
regulation control even at a genome-wide scale. Combination of gene expression studies,
e.g. in human hippocampal tissue, with genome-wide genotyping of SNPs, represents a
possible basis of association studies of genetic markers with individual gene expression.
Previous gene expression studies using human hippocampal tissue, indicate biological
networks to be significant in gene expression changes such as GABA-ergic transmission,
signal transduction and ion transport, glial activation and immune response including
inflammation (Aronica and Gorter, 2007).
An additional advantage of genome-wide assocation (GWA) studies is given by re-
construction of gene networks to identify key regulators of complex disease traits for
further biological validation (Zhu et al., 2004). Such network analyses including gene
expression and genetic data are known to clarify mechanisms underlying multifactorial
diseases, e.g. epilepsy (Chen et al., 2008; Emilsson et al., 2008).
2.6 Aims of this work
Amongst other complex disorders of the CNS such as depression and migraine, epilep-
sies are characterized by episodically aberrant neuronal activity. Mechanisms related
to excitability and neurotransmission play a central role. Intriguingly, several sus-
ceptibility variants have been detected in the promoter regions of related genes in
patients suffering from such neurological disorders (Gratacos et al., 2009; EPICURE
Consortium et al., 2012; Cordoba et al., 2012; Duong et al., 2012). However, functional
consequences of these variants often remained unresolved.
The aim of this work is to investigate the potential impact of SNPs located in transcrip-
tional regulatory regions on the expression of respective genes coding for neurotrans-
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mitter receptors including serotonin receptors as well as genes related to inhibition and
neurotransmission, i.e. genes involved in γ-aminobutyric acid (GABA)-ergic homeosta-
sis on the basis of human surgical hippocampal brain tissue.
The first objective is targeted by a candidate-based approach using previously reported
associations between promoter SNPs and changes in gene expression. Do promoter
variants qualitatively and quantitatively influence corresponding gene expression and
as a consequence, aspects of disease susceptibility and generation? We therefore will
perform comprehensive functional studies based on our unique access to fresh frozen
human surgical hippocampal brain tissue of pharmacoresistant TLE patients. First,
we will examine potential allele-specific mRNA expression changes of relevant genes
using the real-time RT-PCR approach. We will pay special attention to mechanisms of
altered promoter control via regulatory SNP influence or TF effects. In order to eluci-
date binding sites for TFs involved in the regulation of corresponding genes and their
potential modification by promoter SNPs, we will apply a detailed bioinformatic anal-
ysis. For the verification of aberrant TF activation due to presence of allelic promoter
variants, we will carry out luciferase reporter gene assays and chromatin immunopre-
cipitation assays (ChIP). Furthermore, given the potential impact of seizure frequency
on gene expression, we will analyze the correlation of gene expression levels in surgical
hippocampi from TLE patients with clinical or functional parameters such as gender,
antiepileptic drug treatment, age at seizure onset and seizure frequency.
Adressing these objectives will provide information concerning the functional impact of
transcriptional control modules and allelic promoter variants relevant in distinct patho-
genetic aspects of neurological disorders. This may support the development of novel
treatment strategies for episodic diseases of the CNS by antagonizing transient patho-
genetic promoter activation mechanisms and by interfering with such transcriptional
cascades to provide new perspectives for anticonvulsive therapies.
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3 Promoter variants determine γ-aminobutyric acid
homeostasis-related gene transcription in human
epileptic hippocampi
3.1 Introduction
Clinical and experimental evidence demonstrates epileptic seizures as a consequence
of neuronal hyperexcitability resulting from a chronic imbalance between excitation
and inhibition in the brain (Feng et al., 2008). Gamma-aminobutyric acid (GABA)
represents the predominant inhibitory neurotransmitter in the adult brain (Krnjevic´
and Schwartz, 1967). GABA stimulates both metabotropic and ionotropic GABAA
receptors. The GABAA receptor belongs to the superfamily of ligand-gated ion chan-
nels which mediate the majority of rapid inhibitory neurotransmission in the central
nervous system (Mody and Pearce, 2004; Steiger and Russek, 2004). The binding of
GABA to the GABAA receptor results in chloride influx leading to inhibitory postsy-
naptic currents (Mody and Pearce, 2004). Commonly, GABAA receptors are composed
of five from at least 18 known subunits (α1-6, β1-3, γ1-3, δ, ε, θ, ρ1-3) (Frugier et al.,
2007). Several gene clusters encode for these subunits, such as the GABRA5, GABRB3
and GABRG3 gene cluster residing on chromosome 15q11-12 and encoding for the α5,
β3 and γ3 subunits (Glatt et al., 1997). Several neurological and psychiatric diseases
are known to be associated with changes in GABAA receptor expression. Alterations
in GABAA receptor subunit composition have been reported in TLE patients with
hippocampal sclerosis (Loup et al., 2000).
The GABA β3 subunit has gained our special attention since it plays a role in several
epileptic disorders. As previously reported, it shows a prevalent expression in prenatal
brain regions (Laurie et al., 1992) and is encoded by the GABRB3 gene. Furthermore,
Urak et al. identified the SNP rs4906902 in the promoter region of GABRB3 to be over-
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represented in childhood absence epilepsy (CAE) (Urak et al., 2006). The importance
of GABRB3 in epilepsy is underlined by a GABRB3 knockout mouse model. Disrup-
tion of GABRB3 results in electroencephalographic abnormalities including seizures
(DeLorey et al., 1998).
GABA homeostasis is based on a multilayered and complex system containing several
relevant interacting components. Here, the enzyme succinic semialdehyde dehydroge-
nase (SSADH) is involved in the catabolism of GABA. After conversion of GABA to
succinic semialdehyde by GABA transaminase, SSADH catalyzes succinic semialde-
hyde to succinic acid (Blasi et al., 2002). The impairment of SSADH leads to deficits
in GABA degradation and accumulation of succinic semialdhehyde that is converted
to γ-hydroxybutyric acid (GHB). Previous studies suggested that GHB influences
multiple neurotransmitter systems like dopamine, serotonin, acetylcholine and GABA
by passing through the blood-brain barrier (Maitre, 1997; Nava et al., 2001; Crunelli
et al., 2006). Considering the relevance of GABA homeostasis in epileptic phenotypes,
increased levels of GHB were suggested to contribute to the emergence of seizures
(Snead, 1991; Wong et al., 2003).
The genetic locus for SSADH, ALDH5A1, is located near the tentative susceptibil-
ity loci for juvenile myoclonic epilepsy (JME) (Sander et al., 1997). Intriguingly, a
two-marker haplotype with a trinucleotide repeat polymorphism (rs1883415-TNR) is
detected in the promoter region of ALDH5A1 (Lorenz et al., 2006). This polymor-
phism is associated with JME and idiopathic generalized epilepsy (IGE). Also, the
knockout mouse model of ALDH5A1 develops seizure disorders progressing from ab-
sence seizures to lethal status epilepticus (SE) (Cortez et al., 2004).
Here, we focused on two potentially cis-acting SNPs located in the promoter regions of
GABA homeostasis-relevant genes. While the SNP rs4906902 identified in the promoter
region of GABRB3 is known to be associated with CAE, the SNP rs1883415 in the pro-
moter region of ALDH5A1 is associated with JME and IGE. In order to determine the
potential impact of those promoter polymorphisms to relevant gene expression levels,
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we used the access to human surgical brain tissue of TLE patients. We first strati-
fied TLE patients according to their corresponding SNP genotypes. Subsequently, we
utilized a combinatorial approach including molecular genetic, bioninformatic and in
vitro studies to examine the effects of SNP rs4906902 and SNP rs1883415 in modified
gene transcription and binding affinity of TFs.
The following manuscript published in December 2011 in the Journal of Neuropathology
and Experimental Neurology is permitted to be reused in dissertations and theses ac-
cording to Wolters Kluwer Health and the Copyright Clearance Center’s Rightslink
service.
My contribution to this work comprises the sample slice preparation, DNA and mRNA
isolation, genotyping experiments of candidate SNPs, real-time reverse transcription-
polymerase chain reaction experiments, generation of reporter plasmid constructs for
transient transfections in cell culture and subsequent luciferase assay experiments as
well as the bioinformatic, statistical analyses and writing of the manuscript.
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Abstract
The functional consequences of single nucleotide polymorphisms
associated with episodic brain disorders such as epilepsy and depression
are unclear. Allelic associations with generalized epilepsies have been
reported for single nucleotide polymorphisms rs1883415 (ALDH5A1;
succinic semialdehyde dehydrogenase) and rs4906902 (GABRB3;
GABAA A3), both of which are present in the 5¶ regulatory region of
genes involved in F-aminobutyric acid (GABA) homeostasis. To add-
ress their allelic association with episodic brain disorders and allele-
specific impact on the transcriptional regulation of these genes in human
brain tissue, DNA and messenger RNA (mRNA) isolated from hippo-
campi were obtained at epilepsy surgery of 146 pharmacoresistant mesial
temporal lobe epilepsy (mTLE) patients and from 651 healthy controls.
We found that the C allele of rs1883415 is accumulated to a greater
extent in mTLE versus controls. By real-time quantitative reverse
transcriptionYpolymerase chain reaction analyses, individuals homo-
zygous for the C allele showed higher ALDH5A1 mRNA expression.
The rs4906902 G allele of the GABRB3 gene was overrepresented in
mTLE patients with depression; individuals homozygous for the G
allele showed reduced GABRB3 mRNA expression. Bioinformatic
analyses suggest that rs1883415 and rs4906902 alter the DNA binding
affinity of the transcription factors Egr-3 in ALDH5A1 and MEF-2
in GABRB3 promoters, respectively. Using in vitro luciferase trans-
fection assays, we observed that, in both cases, the transcription fac-
tors regulate gene expression depending on the allelic variant in the
same direction as in the human hippocampi. Our data suggest that
distinct promoter variants may sensitize individuals for differential,
potentially stimulus-induced alterations of GABA homeostasis-relevant
gene expression. This might contribute to the episodic onset of symp-
toms and point to new targets for pharmacotherapies.
Key Words: Egr-3, Epilepsy, Human brain tissue, Luciferase, MEF-2,
Promoter.
INTRODUCTION
Many severe brain disorders, including epilepsy and de-
pression, manifest with episodic rather than permanent or pro-
longed symptoms (1, 2). Alterations of neuronal function in
affected individuals due to mutations within genes related to
excitability and neurotransmission, including ion channels, are
well known (3Y5). However, such familial mutational channel-
opathies generally affect few patients with high penetrance.
Recent data suggest that quantitatively acquired changes of gene
expression, that is, in transcriptional channelopathies, are crit-
ically involved in the pathogenesis of episodic brain diseases
(6Y8). Several susceptibility variants, particularly in the pro-
moter region, have been identified in patients experiencing these
neurologic disorders; these results suggest that alterations of
gene expression mediate pathogenetic effects (9).
Epilepsy surgery provides seizure control in most patients
with pharmacoresistant mesial temporal lobe epilepsy (mTLE)
(10), and hippocampal specimens from these procedures provide
the opportunity for studying the effects of promoter-associated
single nucleotide polymorphisms (SNPs) on the messenger RNA
(mRNA) expression of corresponding genes in the brain tissue.
Because alterations of F-aminobutyric acid (GABA)-ergic inhi-
bition are highly relevant to epilepsy and depression (11Y14), we
focused on the functional role of 2 potentially cis-acting SNPs in
the promoters of GABA homeostasis-relevant genes for tran-
scription. To this end, we stratified mTLE patients according to
their genotypes for expression analyses; this strategy overcomes
the nonavailability of control (i.e. without epilepsy), human hip-
pocampal surgical specimens.
The SNP rs1883415 (A/C) is located 3,750 bp upstream
of the transcription start site of the gene ALDH5A1 that encodes
the aldehyde dehydrogenase 5 family member A1. The minor
allele (C) frequency in a white population represents 34% (Table,
Supplemental Digital Content 1, http://links.lww.com/NEN/A282).
The A allele of this polymorphism, in the context of a 2-marker
haplotype together with a trinucleotide repeat (TAA)11 allele, was
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previously reported as having a significant association with idio-
pathic generalized epilepsy (IGE) and juvenile myoclonic epilepsy
(JME) (15).
The exon 1a promoter region of the GABAA A3 subunit
(GABRB3) gene comprises an A/G polymorphism (rs4906902)
897 bp upstream of the start site of GABRB3. The minor allele
G is found with a frequency of 22% in a white population
according to the dbSNP database (Table, Supplemental Digital
Content 1, http://links.lww.com/NEN/A282) and is overrep-
resented in the absence of epilepsy in childhood (CAE) (16).
GABRB3 is also linked to depression (4, 17).
Initial studies of rs1883415 in ALDH5A1 associated with
IGE and JME, and those of rs4906902 in GABRB3 associated
with CAE (15, 18), have not been replicated. However, there is
inevitably a high false-positive rate of candidate genetic var-
iants and traits, and only few reported associations with such
complex epilepsy forms have been replicated (19). Distinct
pathomechanisms may be related to different forms of epilepsy
syndromes; therefore, the failure to replicate reported associa-
tions does not necessarily disprove the existence of a genetic
susceptibility. Because mTLE shares the feature of transient
onset of hyperexcitability with IGE, JME, and CAE, different
genetic variants may play different roles in mTLE. Here, using
a novel combination of molecular genetic, bioinformatic, and
in vitro molecular biologic approaches, we investigated the
potential roles of rs1883415 and rs4906902 SNPs in impaired
gene transcription and transcription factor (TF) binding in epi-
sodic brain disorders.
MATERIALS AND METHODS
Patient Criteria and Surgical Specimens
Biopsy specimens were obtained from 146 white patients
with chronic pharmacoresistant mTLE who underwent surgi-
cal treatment in the Epilepsy Surgery Program at the University
of Bonn Medical Center (20). Presurgical evaluation using a
combination of noninvasive and invasive procedures revealed
that seizures originated in the mesial temporal lobe in all pa-
tients (21). Surgical removal of the hippocampus was clinically
indicated in every case. All procedures were conducted in ac-
cordance with the Declaration of Helsinki and approved by the
ethics committee of the University of Bonn Medical Center.
Informed written consent was obtained from all patients.
Comprehensive clinical characteristics of patients were avail-
able for our analyses (Table, Supplemental Digital Content 2,
http://links.lww.com/NEN/A283).
Symptoms of depression in the mTLE patients were
assessed according to the Beck Depression Inventory (BDI;
threshold BDI Q12) by experienced psychiatrists at the Uni-
versity of Bonn Neurocenter, and groups of patients with and
without depression were identified (22). It is possible that
patients with mTLE who had not developed depression will
develop it, but the symptoms had not occurred in the ‘‘mTLE
patients without depression’’ group to the time point of this
study. Individuals were followed up for several years because
of their pharmacoresistant mTLE.
All tissue samples were from identical regions of the
hippocampus. Fresh-frozen sections were analyzed according to
international standards and carefully matched for anatomic preser-
vation by experienced neuropathologists (A.J.B. and P.N.) (Table,
Supplemental Digital Content 2, http://links.lww.com/NEN/A283).
Up to five 20-Km-thick tissue sections were used for DNA and
mRNA isolation.
DNA Isolation and SNP Genotyping Analysis
DNA was isolated from tissue specimens using the
DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany), ac-
cording to the manufacturer’s protocol (23). Additional blood
DNA samples were obtained from mTLE patients with depres-
sion before epilepsy surgery (n = 56). Genotyping was performed
with TaqMan SNP Genotyping Assays (ALDH5A1 rs1883415:
C__2479666_1 and GABRB3 rs4906902: C__11300465_10)
(Applied Biosystems, Foster City, CA) on an ABI Prism 9700HT
sequence detection system (PE Applied Biosystems). Allelic dis-
crimination was carried out using the SDS 2.2 software.
RNA and Complementary DNA Preparation
mRNA was isolated as previously described using the
Dynabeads mRNA Direct Micro Kit (Dynal, Oslo, Norway)
according to the manufacturer’s protocol (24). Complemen-
tary DNA (cDNA) was synthesized by reverse transcription
of total mRNA using the RevertAid First-Strand cDNA Syn-
thase Kit (Fermentas, St. Leon-Rot, Germany) following the
manufacturer’s protocol.
Real-Time Reverse TranscriptionYPolymerase
Chain Reaction
ALDH5A1, GABRB3, and synaptophysin were quantified
by real-time reverse transcriptionYpolymerase chain reaction
(PCR) using TaqMan Gene Expression Assays (ALDH5A1:
Hs00542449_m1; GABRB3: Hs00241459_m1; Applied Bio-
systems). Synaptophysin was used as endogenous reference
gene for normalization of the analyzed mRNAs as described
(6, 25). We used the ABI Prism 9700HT sequence detection
system (PE Applied Biosystems) and the relative $$Ct quan-
tification paradigm (6).
Reporter and Other Plasmids
The reporter plasmid under control of the ALDH5A1
promoter containing the polymorphism rs1883415 was con-
structed in 2 steps. First, a 566-bp fragment, bioinformatically
identified as potential core promoter upstream of the transcrip-
tion start site of ALDH5A1, was amplified by PCR using human
genomic DNA as template (cloned Core region: FW-primer
5¶-AAA GCA GCC AGG CAG CAG-3¶, Rev-primer 5¶-GGC
GAC AGG AAA CAG G-3¶), digested with XhoI and BglII, and
cloned into the luciferase reporter vector pGL-3-basic (Promega
Biotech, Madison, WI) (Figure, Supplemental Digital Content 3,
http://links.lww.com/NEN/A284). Subsequently, a 261-bp region
encompassing the ALDH5A1 promoter polymorphism rs1883415
was amplified, cut with XhoI and BglII and cloned 5¶ of the core
promoter in the luciferase reporter plasmid (SNP region: FW-
primer 5¶-ATC CAT GCA ATG TGT GCA G-3¶, Rev-primer
5¶-TTC TGAACCCATTTC TTTGG-3¶). To generate a reporter
plasmid under control of the GABRB3 promoter, a subregion
(927 bp) of the human GABRB3 promoter, including the SNP
rs4906902, was amplified by PCR using human genomic DNA
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as template (FW-primer 5¶-ATC TTT CAGG TAC TGC GGT
CA-3¶, Rev-primer 5¶-CTC CGAGCAGCCAAACG-3¶) (Figure,
Supplemental Digital Content 3, http://links.lww.com/NEN/A284),
cut with XhoI and BglII and cloned into pGL-3-basic.
Transient Transfections
NG108-15 neuroblastoma cells were plated at a density
of 80% confluence in 48-well plates and grown in 0.5 mL of
Dulbecco modified Eagle medium supplemented with 10% vol/
vol fetal calf serum, 5% Pen Strep, and 5% HAT. Transfection
of the cells was carried out using lipofectamine (Invitrogen,
Darmstadt, Germany), following the manufacturer’s protocol.
For each well of the 48-well tissue culture plate, 50 ng of luci-
ferase reporter plasmid, 12.5 ng of pRL-TK or 12.5 ng of RL-
SV40, and 0.5 KL of lipofectamine were mixed with 25 KL of
medium. The mixture was incubated for 20 minutes at room
temperature and then added to the appropriate wells. Cells were
grown in culture medium for 6 to 12 hours at 37-C and 5% CO2.
Thereafter, the medium was replaced by fresh medium, and the
cells were used for experiments 48 hours after transfection.
Luciferase Assay
Renilla luciferase was used to normalize the transfec-
tion efficiency data, and a Dual Luciferase Reporter Assay
System was used according to the manufacturer’s specifications
(Promega). Renilla and Firefly luciferase activities were deter-
mined using the Glomax Luminometer (Promega), counting
each sample 4 times. The results are given as Firefly/Renilla
relative light units (if not otherwise indicated).
Bioinformatic Analyses
The Web and software tools CpGPlot (26), Promoter2.0
(27), COMET (28), and Eponine (29) were used to identify
potential promoter regions upstream of a gene of interest. To
identify the position and conservation of potential TF binding
sites, the software tool PoSSuMsearch (30) using position-
specific-scoring matrices from the TRANSFAC database
(31, 32) was applied to the potential promoter regions. For
filtering the potential TF binding sites, a motif similarity score
(MSS) of 80% was applied.
Statistical Analyses
W2 analysis was used to test significance of differences in
allele and genotype frequencies in controls versus affected sub-
jects. A 2-sided type 1 error rate of p = 0.05 was chosen for the
analyses. No correction for multiple testing was performed with
respect to the exploratory design and modest statistical power of
this study. Analysis of variance t-test was used as indicated to
evaluate the statistical significance of the TaqMan and lucifer-
ase results.
TABLE 1. Genotype and Allele Frequencies of Candidate Single Nucleotide Polymorphisms in Mesial Temporal Lobe Epilepsy
and Control Groups
Genotype Frequency Allele Frequency
SNP Gene Group n AA AC CC W2 p A Allele C Allele W2 p
rs1883415 ALDH5A1 mTLE 140 0.264 (37) 0.572 (80) 0.164 (23) 12.59 0.0019 0.55 (154) 0.45 (126) 8.936 0.0028
Control* 651 0.425 (277) 0.439 (286) 0.135 (88) 0.645 (840) 0.355 (462)
SNP Gene Group n AA AG GG W2 p A Allele G Allele W2 p
rs4906902 GABRB3 mTLE 142 0.669 (95) 0.296 (42) 0.035 (5) 1.2 0.5498 0.817 (232) 0.183 (52) 0.01 0.9918
Control† 561 0.655 (366) 0.324 (181) 0.021 (12) 0.183 (205) 0.817 (913)
Candidate SNPs were described by name of corresponding gene, rsID, and the genotype and allele frequency in mTLE and control groups. Absolutes numbers are shown in
parentheses. W2 test and 2-tailed p value.
None of the genotype distributions in the controls deviated significantly from those expected by Hardy-Weinberg equilibrium.
*Control according to Lorenz et al (15).
†Control according to Urak et al (16).
mTLE, mesial temporal lobe epilepsy; rsID, reference SNP identifier; SNPs, single nucleotide polymorphisms.
TABLE 2. Genotype and Allele Frequencies of Candidate Single Nucleotide Polymorphisms in ‘‘Mesial Temporal Lobe Epilepsy
With Depression’’ Versus ‘‘Mesial Temporal Lobe Epilepsy Without Depression’’ Groups
Genotype Frequency Allele Frequency
SNP Gene Group Depression n AA AC CC W2 p A Allele C Allele W2 p
rs1883415 ALDH5A1 mTLE + 76 0.276 (21) 0.368 (28) 0.355 (27) 13.32 0.0013 0.461 (70) 0.539 (82) 1.348 0.2457
mTLE j 110 0.1 (11) 0.6 (66) 0.3 (33) 0.4 (88) 0.6 (132)
SNP Gene Group Depression n AA AG GG W2 p A Allele G Allele W2 p
rs4906902 GABRB3 mTLE + 81 0.691 (56) 0.198 (16) 0.111 (9) 7.18 0.0276 0.79 (128) 0.21 (34) 0.112 0.7373
mTLE j 107 0.598 (64) 0.355 (38) 0.047 (5) 0.776 (166) 0.224 (48)
Candidate SNPs were described by name of corresponding gene, rsID, and the genotype and allele frequency in mTLE and control dbSNP group. Absolutes numbers are shown in
parentheses. W2 test and 2-tailed p value.
j, absent; +, present; mTLE, mesial temporal lobe epilepsy; SNPs, single nucleotide polymorphisms.
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RESULTS
Distribution of Allelic Variants in Different
Patient Groups
We first examined the allele and genotype frequencies of
the ALDH5A1 and GABRB3 SNPs in 146 mTLE patients and
a German population control group (Table 1) (15, 18). Asso-
ciation analysis for the ALDH5A1 promoter SNP rs1883415
revealed a significant excess of the C allele in 140 mTLE
patients versus controls (W2 = 8.94, df = 1, p = 0.0028). Like-
wise, the genotypic frequencies differed significantly between
mTLE patients and controls (W2 = 12.59, df = 2, p = 0.0019;
Table 1).
For the GABRB3 promoter SNP rs4906902, we did not
observe a significant increase of the A allele in 142 mTLE
patients compared with the 561 German population controls
(W2 = 0.01, df = 1, p = 0.99). The genotype frequencies
were not significantly different (W2 = 1.2, df = 2; p = 0.55;
Table 1).
Because neuropsychiatric (particularly depressive) symp-
toms are frequent in mTLE patients, we further tested a comor-
bidity phenotype by stratifying the patients according to the
presence or absence of depression. We also increased our sample
population with blood DNA samples from additional mTLE
patients with depression (n = 56; BDI Q12). We genotyped
these patients for the 2 respective candidate SNPs (Table 2). The
genotype frequency in mTLE patients with depression versus
mTLE patients without depression was significantly different
for the ALDH5A1 promoter SNP rs1883415 (W2 = 13.32,
df = 2, p = 0.0013), that is, the C allele genotype is significantly
increased in patients with symptoms of depression (Table 2).
Intriguingly, for the SNP rs4906902 located in theGABRB3
promoter, our analysis demonstrated that, in contrast to the entire
TLE patient collective, TLE patients with depressive symptoms
displayed a significant increase of the G/G genotype compared
with TLE patients without depression (W2 = 7.18, df = 2; p =
0.0276; Table 2).
We did not correct for multiple testing in this associa-
tion analysis. Altogether, we performed 4 (partially depend-
ent) tests comparing the genotypic distribution of 2 common
SNPs in 2 phenotype models (mTLE vs controls, mTLE with
depression vs mTLE without depression). In total, 3 of 4 tests
revealed associations at a nominal p value of 0.05. Consid-
ering the exact p values, the significance level of each asso-
ciation can be adjusted for multiple testing according to the
individual perspective. For the expression quantitative trait
loci (eQTL) analyses, we carried out a post hoc exploration to
examine whether the observed association of the SNP geno-
type and mRNA transcript levels might be spurious due to
confounding by several clinical variables that might affect gene
expression, for example, age-of-onset, sex, and age at sampling.
These additional tests were not part of the original study hypo-
thesis and, therefore, were not considered as additional tests re-
quiring a p value adjustment. They did not result in significant
correlations of distinct genotypes to other clinical variables (Table,
Supplemental Digital Content 4, http://links.lww.com/NEN/A285).
These experiments demonstrate intriguing correlations of the
genetic variability of ALDH5A1 and GABRB3 to mTLE and
depression.
mRNA Expression of ALDH5A1 and GABRB3
Is Affected by the Promoter Polymorphisms
Next, we analyzed whether and how the presence of allelic
variants in respective promoters influences the mRNA expres-
sion of ALDH5A1 or GABRB3 in human hippocampal brain
tissue derived from pharmacoresistant mTLE patients during
epilepsy surgery (Figs. 1A, B). We found that the relative gene
expression of ALDH5A1 mRNA in mTLE patients homozygous
for the A allele (n = 18) was significantly decreased compared
with the group of mTLE patients homozygous for the C allele
(n = 19; Fig. 1C; t-test: *, p = 0.037).
The relative expression of GABRB3 mRNA was sig-
nificantly increased in the mTLE patient group with the A/A
genotype (n = 52) compared with hippocampi of mTLE
patients carrying the G/G genotype (n = 4; t-test: *, p = 0.049;
Fig. 1D). Importantly, neither different basic neuropathology
patterns nor clinical variables covaried with the differences in
gene expression observed (Table, Supplemental Digital Con-
tent 4, http://links.lww.com/NEN/A285).
Because antiepileptic drugs may have effects on gene
expression and cause mood disturbances, we analyzed the
effects on gene expression of antiepileptic as well as anti-
depressant drugs (Table, parts A and B, Supplemental Digital
Content 5, http://links.lww.com/NEN/A286). We did not find
significant differences in gene expression according to treatment
with antiepileptic/antidepressant compounds. Furthermore, we
observed no significant overrepresentation of antiepileptic phar-
macotherapy in mTLE patients with depression (Table, part C,
Supplemental Digital Content 5, http://links.lww.com/NEN/A286).
Thus, our data suggest that polymorphisms in the promoter
region of the analyzed target genes can affect corresponding
gene expression independent of the variables examined.
Promoter SNPs Influence the Functionality
of Transcription Factors Regulating Expression
of ALDH5A1 or GABRB3
To examine further whether the above described SNPs
directly affect the DNA binding affinity (and thereby func-
tionality of transcription factors), we searched for TF binding
sites whose MSS was significantly altered by the presence of
the SNP. For rs1883415 in the ALDH5A1 promoter, we pre-
dicted that the TF binding sites for Egr-3 would exhibit a higher
MSS (74%) in the SNP sequence variant comparedwith thewild-
type promoter allele (MSS = 62%; Fig. 2A). Therefore, the effect
of the 2 ALDH5A1 alleles on basal transcription and Egr-3Y
stimulated transcription was determined by measuring Firefly
luciferase 48 hours after transfection. The results showed no
significant difference in basal expression between the 2 alleles.
By contrast, whereas overexpression of Egr-3 did not induce
expression of the C allele, there was a statistically significant in-
crease in rs1883415 allele expression after Egr-3 stimulation
when compared both to the unstimulated C allele (1.7-fold; t-test:
**, p = 0.0028; n = 4 each), as well as to the stimulated A allele
(t-test: , *, p = 0.025; n = 4 each; Fig. 2C).
In the promoter region of GABRB3, we detected a poten-
tial binding site for the activating TF MEF-2 with a higher
binding affinity to the A allele (74%) than to the G allele (66%;
Fig. 2B). The DNA binding affinity of the previously described
J Neuropathol Exp Neurol  Volume 70, Number 12, December 2011 Promoter SNP-Directed Transcription in Human Brain
 2011 American Association of Neuropathologists, Inc. 1083
Copyright © 2011 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
Pernhorst et al J Neuropathol Exp Neurol  Volume 70, Number 12, December 2011
 2011 American Association of Neuropathologists, Inc.1084
Copyright © 2011 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
N-Oct-3 binding site was not affected by the presence of the
polymorphism (80% binding affinity in the A-variant and 81%
in the G-variant [16] and data not shown). We did not observe
an effect of the rs4906902 allelic variants on basal promoter
activity. Interestingly, exposure to increased MEF-2 levels re-
sulted in a significant activation of the A/A genotypic pro-
moter variant (Fig. 2D; 1.8-fold; t-test: ***, p = 0.0009; n = 4
each) but not of the G/G variant (Fig. 2D; n = 4 each).
DISCUSSION
Our data demonstrate that the promoter-localized SNPs
rs4906902 and rs1883415 substantially affect transcription
levels of the corresponding GABA homeostasis-relevant genes
in human brain tissue by putatively altering the binding affinity
of corresponding TFs. Several limitations of the data need to be
considered with respect to their interpretation. In the genetic
analyses carried out in this study, the number of patients avail-
able for analyses did not allow us to replicate a genetic associ-
ation with mTLE. However, in contrast to genetic analyses
alone, in concurrent genetic and expression analyses based on
fresh-frozen patient hippocampal tissue, the number of patients
is (for obvious reasons) more limited. Furthermore, genome/
transcriptome-wide analyses show a large number of eQTLs.
However, it should be noted that eQTL data derived from the
human brain are limited and have been obtained mainly from
postmortem tissue samples that have certain restrictions with
respect to mRNA conservation (33Y35); moreover, comparable
eQTL analyses for bioptic human brain tissues are not avail-
able. Therefore, our approach (although certainly not genome-
wide) concentrated on genes selected according to biologic
plausibility.
Distinct statistically significant associations of rs4906902
allelic variants in the GABRB3 promoter have been reported in
episodic brain disorders. The minor allele G is overrepresented
in childhood absence epilepsy (16), whereas the major allele A
of GABRB3 is linked to depression in patients with posttrau-
matic stress disorder (17). Other data demonstrate that the
GABRB3 exon 1a SNP G allele does not differ significantly
between CAE patients and controls (15, 18). Here, we found
that the G allele was significantly more frequent in mTLE
patients with depression (Tables 1 and 2). Generally, genetic
variation in GABRB3 substantially influences the risk for bipo-
lar disorders (4), and there is apparently no overall abundance of
one particular rs4906902 allele in episodic brain disorders. On
the contrary, both individual alleles are differentially overrep-
resented in patients in whom depressive mood impairment has
its onset in distinct pathologic backgrounds, that is, the A allele
in posttraumatic stress versus the G allele in epilepsy. This ar-
gues that depressive symptoms manifest in diverse contexts by
the contribution of different, potentially even opposite molecular
alterations.
To understand the functional consequences of the presence
of these allelic variants, we investigated whether such genetic
variation affects mRNA transcription. In brain tissue stratified
according to the genotype, we observed substantially different
GABRB3 expression levels dependent on the rs4906902 gen-
otype, that is, a significantly lower expression of GABRB3
mRNA in hippocampi of mTLE patients homozygous for the
G allele compared with those homozygous for the A allele
(Fig. 1D). Reduced availability of the A3 subunit of the GABAA
receptor has been shown to be epileptogenic, that is, its dele-
tion in mice leads to severe behavioral deficits and epilepsy
(36). GABAA receptorYmediated miniature inhibitory post-
synaptic currents in cortical neurons in cultures from A3j/j
mice are faster than of littermate controls and more prolonged
by zolpidem (36). However, in human mTLE hippocampi,
increased mRNA and protein levels have been observed for
the GABAA receptor A3 subunit in the dentate molecular
layer and in the subiculum (37). These data suggest distinct
allelic variant accumulation with opposite consequences for
GABRB3 mRNA expression in patient subgroups with epilepsy
and depression. With respect to promoter control in the region of
rs4906902, our bioinformatic prediction suggested substantially
differential binding for MEF-2, with a higher affinity for the
A allele. Similar to previous data, we found a tendency to in-
creased basal activity of the G allele GABRB3 promoter variant
(16), which was, however, not significant. Stimulation of the
GABRB3 promoter with MEF-2 revealed a substantial acti-
vation of the A allele, whereas the G allele showed virtually no
promoter activation (Fig. 2). However, after pilocarpine-
induced status epilepticus in rats, there is reduced hippocampal
expression of MEF-2 mRNA compared with controls (unpub-
lished data). These data would be compatible with a generally
attenuated activation of the GABRB3 promoter in mTLE hip-
pocampi. Interestingly, MEF-2 target genes have diverse func-
tions at synapses, and several of them are linked to epilepsy and
depression (38). Considering GABAA A3 as an active com-
ponent of ligand-gated ion channels, our data on rs4906902
FIGURE 1. Analysis of relative gene expression of candidate genes ALDH5A1 and GABRB3 in human hippocampal tissue. (A)
Hematoxylin and eosin staining shows the characteristic pattern of Ammon horn sclerosis (AHS) in a hippocampal biopsy specimen
after epilepsy surgery of a pharmacoresistant mesial temporal lobe epilepsy (mTLE) patient (gray asterisk, dentate gyrus [DG]
granule cell layer; black asterisk, CA4; white asterisk, CA2; black arrows, CA1). (B) There is segment neuronal cell loss most
pronounced in CA4 and CA1; CA2 and DG are well preserved (NeuN immunohistochemistry). (C) There is marked astrogliosis in
the hippocampal formation (glial fibrillary acidic protein immunohistochemistry). (D) Quantitative determination of candidate
gene mRNAs was carried out using a TaqMan approach. In a representative trace, the increase of fluorescence intensity demon-
strating the specific amplification is shown for the ALDH5A1 wild-type (triangles), ALDH5A1 single nucleotide polymorphisms (SNP)
(squares) and reference (black curve) mRNAs. The horizontal line marks the point of the polymerase chain reaction in the expo-
nential stage where ‘‘threshold cycles’’ are determined for quantification of target genes. (E) For ALDH5A1, the relative gene
expression in patients homozygous for the wild-type allele A (n = 18; 0.35 T 0.04; black bar) is significantly lower compared with
that for the group of mTLE patients homozygous for the SNP C (n = 19; 0.48 T 0.05; t-test: *, p = 0.037; light gray bar). (F) Relative
expression of the GABRB3 mRNA in the group of patients homozygous for the wild-type allele A (n = 52; 0.16 T 0.01; black bar) is
significantly higher compared with that in the group of patients homozygous for the SNP allele G (n = 4; 0.1 T 0.02; t-test: *, p =
0.049; light gray bar). Scale bar = (AYC) 2.0 mm.
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provide an intriguing example of a transcriptional channelop-
athy in the human brain that can contribute to the pathogenesis
of CNS disorders.
In contrast to the immediate effects on neurotransmission
by GABAA A3, ALDH5A1 encodes the succinic semialdehyde
dehydrogenase, a protein that catalyzes a critical step in the
recycling and degradation of GABA (39, 40). Its deficiency
results in a rare autosomal-recessive heritable disorder with pro-
minent seizures; there are also seizures in a murine model of
this deficiency (41). One of the ALDH5A1 rs1883415 alleles
for which we stratified patients here (i.e. the A allele) is sig-
nificantly accumulated in IGE and JME (15). Here, we con-
sistently observed a reduced expression of ALDH5A1 mRNA
in the brain tissue of patients homozygous for this (Fig. 1C).
This finding is in line with a reduced expression of the succi-
nic semialdehyde dehydrogenase and the hypothesis of a lower
turnover of GABA, which may at least partially parallel the
functional consequences of a complete lack of the succinic
FIGURE 2. Analysis of transcription factor (TF) binding site modifications and relative luciferase activity in promoter regions of
candidate genes. (A) The single nucleotide polymorphism (SNP) rs1883415 is located in the promoter region of the ALDH5A1
gene 3,722 bp upstream of its transcription start site. The genomic sequence flanking the SNP contains potential TF-binding sites,
characterized by different matrix similarity scores between the wild-type and SNP sequence variants. Egr-3, an ‘‘activating’’ TF,
binds with a higher affinity (74%) to the SNP sequence compared with the wild-type promoter allele (62%). (B) The upstream
region of GABRB3 contains a SNP (rs4906902) located 841 bp upstream of exon 1 of GABRB3. This SNP is located within a potential
binding site for the ‘‘activating’’ TF MEF-2 (large box), which is predicted to bind with a higher binding affinity to the wild-type
variant (74%) than the SNP allele (66%). (C) The increase of the promoter activity of the ALDH5A1 fragment homozygous for the
SNP allele is significant after exposing the promoter to Egr-3 (10.0 ng of plasmid; 1.7-fold; t-test: **, p = 0.0028; n = 4 each; light
gray bars). The wild-type promoter fragment shows no significant difference in fold change activity after the addition of Egr-3
expression plasmid compared with basal controls (n = 4 each; black bars). There is substantially stronger activation of the promoter
fragment carrying the SNP compared with wild-type after exposure of both genotype promoters to Egr-3 (t-test: *, p = 0.025; n = 4
each). There was no significant difference in the relative luciferase activity of the basal promoters. (D) The activity of the GABRB3
promoter fragment homozygous for the wild-type allele is significantly increased in fold change after exposure to MEF-2 (10 ng of
expression plasmid; 1.8-fold; t-test: ***, p = 0.0009; n = 4 each; black bars). The promoter fragment containing the SNP allele did
not show significant activity alterations after exposure to MEF-2 (n = 4 each; light gray bars). There was substantially stronger
promoter activity for the wild-type than the SNP variant exposed to MEF-2 (t-test: **, p = 0.007; n = 4 each). The relative luciferase
activity of the basal promoter fragments did not differ between the genotypes.
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semialdehyde dehydrogenase in patients with genetic deficiency
of the molecule. Conversely, we observed abundance of the
ALDH5A1 C allele in the entire mTLE series, as well as in
mTLE patients with depression.
These data suggest that proper availability of the succinic
semialdehyde dehydrogenase and ‘‘fine-tuning’’ of the homeosta-
sis of GABA degradation are critical for adequate neurotransmis-
sion; not only reduced levels of the semialdehyde dehydrogenase
but also its increased levels may impair neuronal function in a
way that contributes to different clinical manifestations includ-
ing mood disorders and focal seizures. Unfortunately, we did
not have sufficient amounts of patient fresh-frozen brain tissue
available to carry out comparisons of ALDH5A1 mRNA expres-
sion in mTLE patients with and without depressive symp-
toms. With respect to potential promoter control mechanisms,
we identified a highly conserved Egr-3 binding site located at
the rs1883415 SNP. Intriguingly, the C allele shows stronger
promoter activation after stimulation with Egr-3. Egr-3 mRNA
is increased in the hippocampal formation after status epilep-
ticus induced by kainic acid in a rat temporal lobe epilepsy
model (42). These data would be compatible with an increased
stimulus by Egr-3 on the expression of the respective gene in
individuals harboring the ALDH5A1 rs1883415 C allele. Fur-
thermore, Egr-3 has also been associated with the control of
the expression of the >4 subunit of the GABAA receptor (43).
Our present data suggest that, in human mTLE, impairment of
GABA signaling may be due not only to the dynamic expres-
sion of GABA receptor subunits themselves but also to the
degradation-relevant molecules, that is, succinic semialdehyde
dehydrogenase.
With respect to GABA-mediated signaling, the aberrant
expression of mRNAs coding for GABA receptor subunits
and GABA-degrading enzymes may combine functionally and
contribute to a disturbed neurotransmission in affected brain
tissue. Our data suggest a relevance of genetic promoter vari-
ants for the expression of corresponding genes in the brain tis-
sue of patients experiencing episodic CNS disorders. In the
future, genetic profiling of such variants may open the perspec-
tive to enable ‘‘personalized’’ pharmacotherapies more effective
for chronic recurrent brain disorders.
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Pernhorst et al., Supplemental Table 1, Supplemental Digital Content 1:
Information of  selected candidate SNPs.  Reference SNP IDs (rsIDs),  name of 
nearest gene with  the corresponding distance to the TSS* in base pairs and the 
position of the SNP are represented. For each candidate SNP the different occurring 
alleles, the minor allele and the frequency of the allele in the Caucasian population 
(source: dbSNP) is shown. The documented location of the SNP according to dbSNP 
is presented as well. 
rsID Gene SNP Positi-on
Distance 
to TSS* Alleles
Minor 
allele
Frequency in 
CEU** 
Location of 
SNP
rs1883415 ALDH5A1 chr.6, 24599454 - 3750bp A/C C 0.345 nearGene-5***
rs4906902 GABRB3 chr.15, 24570861 - 897bp A/G G 0.221 nearGene-5***
*TSS = Transcription Start Site
**CEU = Utah residents with Northern and Western European ancestry from the CEPH collection
***nearGene-5 = SNP is 5’ to and 2kb upstream of gene
Pernhorst et al., Supplemental Table 2, Supplemental Digital Content 2: 
Summary of patient parameters. 
Parameters including gender, depression, number of seizures per month, seizure-
free post-operative interval, age at seizure onset in years, age at epilepsy surgery in 
years, pathology and drug therapy are presented for each patient.  Information on 
number of seizures per month relies partially on patients’ information and is therefore 
variable (n.a.: data not available). The post-operative outcome is classified according 
Engel  classification  (class  I  A:  completely  seizure  free;  class  I  B:  non  disabling, 
simple partial seizures only; class II B: free of disabling seizures for at least 2 years;  
class  IV  B:  no  seizure  reduction).  Biopsy  specimens  were  neuropathologically 
analyzed according to standard procedures and hippcampi stratified according to the 
pathlogical pattern of the patient into the three following groups: AHS (Ammon’s horn 
sclerosis),  Rasmussen’s  encephalitis  and  lesion  associated  (ganglioglioma, 
cavernoma,  dysembryoplastic  neuroepithelial  tumor).  Notably,  also  hippocampi  of 
patients  with  Rasmussen’s  encephalitis  (RE)  and  lesion  associated  TLE  show 
substantial  reactive  astrogliosis  in  the  hippocampal  formation.  Drug  therapies  do 
generally consist of combinations of the following compounds, i. e. Carbamazepine 
(CBZ),  Clobazam (CLB),  Lamotrigine  (LTG),  Levetiracetam  (LEV)  Oxcarbazepine 
(OXC), Phenytoin (PHT), Phenobarbital (PB), Pregabalin (PGB), Topiramate (TPM), 
Valproat (VPA), Vigabatril (VGB) and Zonisamide (ZON). 
Patient Gender Depression
Number 
of 
seizures 
per 
month
Seizure-
free Post-
operative 
interval
Age at 
seizure 
onset in 
years
Age at epi-
lepsy sur-
gery in 
years
Pathology Drug thera-py
1 female yes 1-3 CPS I A 6 47 AHS LEV, CBZ
2 male no 2 CPS per day I A 11 11
lesion asso-
ciated CBZ, LTG
3 male no 5 CPS I A 3 19 AHS VPA
4 male yes 2–4 CPS I A 40 48 AHS LTG, ZON
5 male no 3-7CPS IV B 10 45 AHS LTG, CBZ, VPA
6 female no daily IV B 1 38 AHS VPA, LTG
7 female no 4 CPS IV B 20 32 AHS n.a.
8 female no 2-3 CPS I A 1 35 AHS LTG
9 male yes n.a. IV B n.a. 39 n.a. n.a.
10 male no 4-6 CPS IV B 13 19
lesion asso-
ciated
CBZ , 
VGB , CLB
11 male n.a. 30 CPS IV B 21 39 lesion asso-ciated
TPZ, CBZ, 
PHT, LEV
12 female yes 6-8 CPS IV B 13 46 AHS OXC
13 male yes 3 CPS IV B 7 29 lesion asso-ciated
LEV, LTG, 
ZON, PB, 
PHT
14 male no 2-3 CPS IV B 6 45 AHS OXC, LTG
15 female no 3 CPS per day I A 1 10 AHS CBZ, VPA
16 male no 2 CPS I A 5 8 AHS n.a.
17 female yes 3 CPS IV B 6 n.a. AHS n.a.
18 male no 3-4 CPS IV B 18 28 AHS LTG, CLB
19 female yes 3-10 CPS I A 18 44 AHS
OXC, LTG, 
GBP
20 male yes 3 CPS IV B 46 58 AHS LTG, LEV
21 female yes 3-4 CPS IV B n.a. 36 AHS LTG, CBZ
22 female no 2 CPS IV B 12 20 AHS LEV, LTG
23 female no 8 CPS I B 4 50 AHS VPA
24 female no 3 CPS IV B 3 24 lesion asso-ciated VPA, CBZ
25 female yes 2 CPS I A n.a. 29 AHS CBZ, LTG
26 male yes 6 CPS I A 3 24 AHS LEV, LTG, CBZ
27 female no 2-3 CPS I A 13 25 AHS LEV, CBZ
28 female no 1-2 CPS IV B 1 11 AHS LEV
29 female no 1-2 CPS I A 1 29 AHS LEV, OXC
30 female no 3 CPS I A 1 8 n.a. LEV, PGB, CLB, MSM
31 female yes 2 CPS IV B 2 8 AHS LEV
32 male n.a. 2 CPS n.a. 2 8 n.a. LEV, CLB
33 male no 2-4 CPS IV B 10 56 AHS
ZON, VPA, 
OXC
34 male yes 1 CPS I A 30 38 AHS LTG, PHT
35 female no 3 CPS per day I A 4 0 AHS
LEV, TPM, 
CBZ
36 female yes 16 CPS n.a. 13 39 AHS OXC, LEV, LTG
37 female no 2-4 CPS I A 5 41 AHS LEV, CBZ
38 male no 3-4 CPS IV B 19 31 AHS VPA, CBZ
39 female no 3-15 CPS I A 2 24 AHS
LEV, LTG, 
ZON
40 male no 1 CPS IV B 16 56 AHS LEV
41 male no 15-20 CPS I A 10 15 AHS CBZ
42 male no 8 CPS I A 9 10 lesion asso-ciated LTG
43 female no
5 CPS 
per 
year
I A 10 19 lesion asso-ciated CBZ
44 female no 24 CPS IV B 4 45 AHS CBZ
45 male no 33 CPS I A 25 35 AHS CBZ
46 male no 20 CPS I A 12 26 AHS CBZ, GBP
47 female no n.a. I A 7 16 lesion asso-ciated n.a.
48 male no 3 CPS IV B 7 24 lesion asso-ciated VPA
49 female no 2 CPS IV B 1 14 AHS LEV
50 female no
1 CPS 
per 
week
I A 1 42 AHS TPM, VPA
51 female no 2 CPS per day n.a. 1 32 AHS CBZ, GBP
52 male yes 6-12 CPS IV B 27 50 AHS OXC, PHT
53 female yes 2 CPS IV B 14 22 lesion asso-ciated LTG, LEV
54 male no 4 CPS IV B 5 32 lesion asso-ciated CBZ, LTG
55 male no n.a. n.a. 7 n.a. AHS n.a.
56 male no
3 CPS 
per 
week
I A 44 59 AHS LTG, TPM, CLB
57 male n.a. 15-20 CPS I A 1 38 AHS CBZ, TPM
58 male yes 4 CPS IV B 29 37 lesion asso-ciated LEV
59 male no 30-40 CPS I A 3 17 AHS OXC, LTG
60 female no 4 CPS I A 3 37 AHS CBZ, LTG
61 male no 5-8 CPS IV B 3 33 AHS VPA
62 male yes 2 CPS I A 2 19 lesion asso-ciated
LTG, OXC, 
TPM
63 male no 1-2 CPS IV B 28 52 n.a. LTG, LEV
64 female no 2-3 CPS IV B 22 54 AHS
LEV, TPM, 
OXC
65 female no 11-14 CPS IV B 20 36
lesion asso-
ciated CBZ, CLB
66 female no 1 CPS per day I A 0 2
lesion asso-
ciated LTG, PB
67 female no 1-2 CPS IV B 15 32 AHS CBZ
68 male no 3-5CPS I A 8 14 AHS LTG, ZON
69 male no n.a. I B n.a. n.a. lesion asso-ciated n.a.
70 male no 1 CPS per day I A 2 4 AHS LEV, LTG
71 male no 1-2 CPS IV B 12 31 AHS LTG, CBZ
72 male no 60 CPS I A 5 10 RE LEV, VPA, CBZ
73 male no 2 CPS IV B 6 45 AHS LTG, CBZ
74 female yes 4-5 CPS I A 1 39 AHS
VPA, PHT, 
PB
75 male no 4 CPS n.a. 7 41 n.a. CBZ, VPA, LTG
76 female no 4-5 CPS IV B 3 32 AHS VPA, PHT
77 male no 4-6 CPS I A 2 24 AHS CBZ, PGB
78 female no 2 CPS I A n.a. 32 AHS n.a.
79 female no 7-8 CPS I A n.a. 35
lesion asso-
ciated LTG
80 female no
2-3 
CPS 
per 
week
I B 12 31 lesion asso-ciated OXC
81 female yes 4-5 CPS IV B 2 34 AHS CBZ, VPA
82 male yes 0-1 CPS I A 39 41 AHS PHT, LTG
83 male no 6 CPS I A 25 30 AHS LEV, OXC
84 female yes 1 CPS IV B 12 46 AHS LTG, PB
85 male no 2-9 CPS I A 8 56 AHS CBZ
86 male no 3-10 CPS II B 13 31 AHS VPA, CBZ
87 female yes
1-2 
CPS 
per 
year
I A 22 28 RE LTG
88 female no 1 CPS per day I A 11 25 AHS LTG, LEV
89 female no 2 CPS I A 28 38 AHS n.a.
90 female no 3-12 CPS IV B 15 18 AHS
LEV, OXC, 
PB
91 female no 2 CPS I A 3 34 AHS CBZ
92 male yes 4-8 CPS II B 12 30 AHS CBZ, TPM
93 male no 1-2 CPS I A 20 46 AHS CBZ
94 male no 15 CPS I A 4 12 AHS ZON
95 female no 1 CPS I A 1 37 AHS CBZ
96 female no 20 CPS I A 6 43 AHS CBZ, TGB
97 male yes 10-20 CPS IV B 7 71 AHS LEV, LTG
98 male no 2-3 CPS n.a. 1 10 AHS
VPA, VGB, 
PHT, PB
99 male yes
1 CPS 
per 
week
IV B 12 62 AHS CBZ, TPM
100 male no multiple CPS I A 12 27 AHS LEV, CBZ
101 female no 4 CPS IV B 0 31 AHS CBZ, LEV, LTG
102 female yes 4 CPS I A 13 52 AHS VPA, TPM
103 male no 2-4 CPS IV B 9 43 AHS OXC, TPM
104 female no
1 CPS 
per 
week
IV B 32 34 AHS OXC, LTG, LEV, LZP
105 female no weekly IV B 1 22 AHS PGB, CBZ
106 female no 9-12 CPS I A 23 31 AHS LEV, VPA
107 male no n.a. IV B n.a. n.a. AHS n.a.
108 male no 3-9 CPS IV B 2 38 AHS CBZ, VPA
109 female no 3-9 CPS II B 1 46 AHS CBZ, VPA
110 male no 1 CPS per day IV B 10 28
lesion asso-
ciated PGB, LTG
111 female no 2 CPS I A 8 17 AHS TPM
112 female no 4 CPS I A 7 32 AHS LTG, CBZ
113 female no 10 CPS I A 5 51 AHS LEV, CBZ
114 female no 8 CPS I A 2 20 lesion asso-ciated LEV, LTG
115 male no
4 CPS 
per 
year
IV B 10 31 AHS VPA, CBZ
116 female no 4 CPS I A 0 5 AHS CBZ, LTG
117 male no 1 CPS II B 17 28 lesion asso-ciated TPM, GBP
118 female no 3 CPS II B 17 26 AHS VPA
119 female yes 8 CPS IV B 24 29 AHS LTG
120 female no 2-4 CPS IV B 29 40 AHS LTG, TPM
121 male no
Multiple 
per 
night
I A 6 13 AHS OXC, PRM
122 female no 1 CPS per day I A 8 55
lesion asso-
ciated VPA, CBZ
123 male no 4 CPS I A 40 60 AHS LTG, LEV
124 male no 40 CPS IV B 4 42 AHS CBZ
125 male no 4 CPS I A 2 19 AHS OXC, LEV
126 male yes 9 CPS I A 32 39 lesion asso-ciated
LEV, TPM, 
CBZ
127 female no 1 CPS I B 5 10 AHS VPA, PHT
128 male no 4 CPS IV B 11 54 AHS LEV, CBZ
129 female no
3 CPS 
per 
week
I A 24 60 lesion asso-ciated CBZ, LEV
130 male yes 1-8 CPS IV B 3 21 AHS CBZ, TPM
131 male no 4-8 CPS IV B 13 50 AHS CBZ, CLB
132 male yes 20-30 CPS I B 2 34 AHS LEV, CBZ
133 male no 2 CPS IV B 28 41 lesion asso-ciated CBZ, LTG
134 female no 2 CPS IV B 17 32 AHS CBZ, TPM
135 female no 1 CPS IV B 13 31 AHS CBZ, LTG
136 male no 2 CPS per day I A 1 5 AHS LTG
137 male no 2-3 CPS IV B 5 44 AHS CBZ
138 male no n.a. IV B 1 3 lesion asso-ciated LTG, CBZ
139 male no
2-3 
CPS 
per day
I A 3 32 AHS CBZ, LTG
140 female no 2-8 CPS I A 7 62 AHS
LEV, CBZ, 
PGB
141 female no 2 CPS IV B 11 12 lesion asso-ciated CBZ, VGB
142 male yes 3 CPS IV B 3 42 AHS CBZ
143 female no 1-2 CPS IV B 24 47 AHS
Cbz1200 + 
2000
144 male no 1 CPS IV B 4 31 AHS CBZ, GBP
145 male no 5 CPS I A 2 31 AHS CBZ, LTG, CNZ
146 male no 8 CPS I A 13 30 AHS LTG, CBZ
147 female yes 2 CPS IV B 25 57 AHS LEV, CBZ
148 male no 15 CPS n.a. 1 35 AHS CBZ
149 female yes 2 CPS n.a. 16 24 n.a. PGB, LEV, OXC
150 male yes 1 CPS I A 8 42 AHS VPA, LEV
151 male yes 1 CPS n.a. 12 n.a. n.a. LEV
152 male yes 0-1 CPS n.a. 30 n.a. n.a. OXC, ZON
153 female yes 15 CPS n.a. 16 n.a. AHS LTG, PGB
154 male yes n.a. n.a. n.a. n.a. n.a. n.a.
155 female yes 3 CPS I B 38 41 n.a. LEV, LTG
156 male yes 3 CPS I A 27 53 AHS PHT
157 female yes 2 CPS I A 20 38 lesion asso-ciated LEV, LTG
158 male yes 0 CPS n.a. n.a. n.a. lesion asso-ciated n.a.
159 male yes 30 CPS I B 27 36 lesion asso-ciated
ZON, PB, 
LEV, CBZ
160 male yes 0-1 CPS n.a. 9 n.a. n.a. TPM, LEV
161 female yes 3 CPS n.a. 43 45 n.a. LEV, LTG
162 male yes 4-6 CPS IV B 4 30
lesion asso-
ciated CBZ, VPA
163 female yes 1 CPS n.a. 2 n.a. n.a. LEV
164 male yes 4 CPS I A 23 50 AHS LEV, TPM, PGB
165 female yes 30 CPS I B 16 20 AHS LEV, VPA, OXC
166 male yes 2 CPS I A 6 26 AHS VPA, ZON
167 male yes
1-2 
CPS 
per 
week
I A 16 19 AHS VPA
168 female yes < 1 CPS n.a. n.a. n.a. n.a. LEV, CBZ
169 female yes < 1 CPS n.a. 6 n.a. n.a. LEV, LTG
170 female yes 0-1 CPS n.a. 7 n.a. n.a. LTG, LEV
171 female yes < 1 CPS n.a. n.a. n.a. n.a. LEV, LTG
172 male yes 4 CPS n.a. 5 35 AHS LEV, CBZ
173 female yes 3 CPS I A 5 54 AHS LTG, OXC
174 male yes < 1 CPS n.a. 12 n.a. n.a. LEV, CBZ
175 male yes 1 CPS IV B 13 50 lesion asso-ciated LTG
176 male yes 4 CPS I A 25 n.a. n.a. PHT
177 female yes < 1 CPS n.a. 48 n.a. n.a. n.a.
178 female yes 4 CPS II B 4 36 AHS CBZ, VPA, TPM
179 female yes < 1 CPS n.a. 49 n.a. n.a. n.a.
180 female yes 2 CPS n.a. 6 56 AHS LTG, CBZ
181 male yes 3 CPS per day I A 1 29 AHS
LEV, PGB, 
VPA
182 female yes 2 CPS I A 47 52 lesion asso- LEV
ciated
183 female yes
1 CPS 
per 
week
IV B 33 37 AHS LTG, LEV
184 male yes 6 CPS n.a. 3 n.a. n.a. LEV, LTG
185 male yes < 1 CPS n.a. 6 n.a. n.a. LEV, LTG
186 male yes
5-6 
CPS 
per 
week
IV B 9 33 AHS LTG, CBZ
187 male yes 60 CPS n.a. 4 n.a. n.a. LEV, PGB
188 male yes 4 CPS n.a. 30 n.a. n.a. LEV, PGB, PB
189 female yes 6 CPS I A 29 44 lesion asso-ciated LTG, LEV
190 male yes 0-1 CPS IV B 34 65
lesion asso-
ciated CBZ, LEV
191 female yes 0-1 CPS n.a. 12 n.a. n.a.
LEV, LTG, 
VPA
192 male yes < 1 CPS n.a. 39 n.a.
lesion asso-
ciated LEV, LTG
193 female yes 3 CPS n.a. 3 n.a. AHS VPA, OXC
194 female yes 3 CPS n.a. 32 n.a. n.a. LEV, VPA, PRM
195 male yes 1 CPS I A 6 45 AHS CBZ
196 male yes
< 1 
CPS in 
2 years
n.a. 6 n.a. n.a. CBZ, LEV
197 male yes 0-1 CPS I A 28 35
lesion asso-
ciated OXC, LEV
198 female yes 4 CPS I A 13 28 AHS LEV, CBZ
199 male yes n.a. I B 20 21 lesion asso-ciated n.a.
200 female yes 7 CPS I A 11 53 AHS LEV, LTG
201 male yes 1 CPS I A 30 34 AHS LEV, PGB
202 male yes n.a. IV B 29 n.a. n.a. CBZ, LTG
203 male yes
2 CPS 
per 
year
n.a. 2 n.a. n.a. LEV, CBZ, PB
Pernhorst et al., Supplemental Figure 1, Supplemental Digital Content 3
A
B
LuciferasepGL3-basic ALDH5A1 promoter
TTCTACAGcCTGTGC
827bp
LuciferaseALDH5A1 promoterpGL3-basic
TTCTACAGaCTGTGC
827bp
LuciferasepGL3-basic GABRB3 promoter
TGCATTaATTTTAAA
927bp
LuciferaseGABRB3 promoterpGL3-basic
TGCATTgATTTTAAA
927bp
Luciferase reporter constructs including different promoter variants of candidate genes. 
(A) We inserted a 827bp promoter fragment (black box) of the predicted promoter region upstream of the 
ALDH5A1 gene upstream of the luciferase reporter gene. The short sequences above the fragments 
represent the different promoter variants (a lowercase c for the wildtype and a lowercase a for the SNP 
variant). (B) We cloned two different 927bp long fragments of the putative GABRB3 promoter region in 
front of the luciferase reporter gene. The sequence variations were denoted by lowercase letters (a for the 
wildtype fragment and g for the SNP fragment).  
Pernhorst et al., Supplemental Table 3, Supplemental Digital Content 4:
Genotype distributions of candidate SNPs
A post-hoc testing  of  the  genotype  distributions  of  the  candidate  SNPs stratified 
according  to  distinct  individual/clinical  characteristics.  Variables  are  expressed  in 
absolute  numbers.  A Χ²-test  was  applied  with  a  type  I  error  rate  of  P  =  0.05. 
Intriguingly, this co-variance analysis results in only depressive symptoms from the 
list of individual clinical parameters to correlate significantly with distinct genotypes of  
the  genes  under  study  (Post-operative  outcome  again  according  to  Engel’s 
classification).
A) Clinical data of mTLE patients: correlation to ALDH5A1 genotypes.
Genotypes
Clinical characteristics AA AC CC Χ² P
 
Gender (Male / Female) 16/17 48/48 34/25 1.06 0.59
 
Depression (yes / no) 22/11 28/66 26/33 14.1 0.001
 
Number of seizures per month  (0-10 
/ 11-20 / 21- more than 100) 28/0/4 66/12/14 43/5/9 5.27 0.26
 
Seizure-free post-operative (I A/ I B/ 
II B/ IV B) 9/3/0/12 44/2/4/33 27/2/2/19 6.62 0.35
 
Age at seizure onset in years (1-10 / 
11-50) 16/14 57/36 26/31 3.54 0.16
 
Age at epilepsy surgery in years (1-
10 / 11-64) 3/22 10/75 2/49 2.57 0.31
 
Pathology  (AHS /  Rasmussen’s en-
cephalitis / lesion associated) 23/0/4 69/1/17 37/1/11 1.32 0.9
 
Drug therapy (sodium channel block-
er monotherapy / levetiracetam com-
binations / non-levetiracetam com-
binations)
5/15/10 21/32/37 14/22/20 2.3 0.68
B) Clinical data of mTLE patients: correlation to GABRB3 genotypes.
Genotypes
Clinical characteristics AA AG GG Χ² P
Gender (Male / Female) 64/60 28/25 10/4 1.99 0.4
Depression (yes / no) 57/64 15/38 9/5 8.08 0.017
Number of Seizures per month  (0-
10 / 11-20 / 21- more than 100) 89/12/18 38/4/9 11/1/0 2.69 0.61
Seizure-free post-operative (I A/ I B/ 
II B/ IV B) 53/6/3/39 19/2/3/24 6/1/0/4 4.09 0.66
Age at seizure onset in years (1-10 / 
11-50) 63/51 29/23 5/9 2.02 0.39
Age at epilepsy surgery in years (1-
10 / 11-64) 10/95 5/43 0/11 1.21 0.64
Pathology  (AHS /  Rasmussen’s 
encephalitis / lesion associated) 76/2/23 39/0/12 9/0/2 1.4 0.86
Drug therapy (sodium channel 
blocker monotherapy / levetiracetam 
combinations / non-levetiracetam 
combinations)
28/47/37 10/19/23 3/7/3 3.17 0.53
C) Clinical data of mTLE patients: correlation to gene expression of ALDH5A1
Clinical variables Mean SEM P
Gender (Male / Female) 0.45 / 0.38 0.06 / 0.03 0.354
Depression (yes / no) 0.41 /0.41 0.09 / 0.03 0.969
Number of Seizures per month  (0-10 / 11- more 
than 100) 0.41 / 0.45 0.03 / 0.09 0.607
Seizure-free post-operative (I A +II B/ I B + IV B) 0.43 / 0.40 0.05 / 0.04 0.734
Age at seizure onset in years (1-10 / 11-50) 0.41 / 0.41 0.05 / 0.04 0.998
Age at epilepsy surgery in years (1-10 / 11-64) 0.39 / 0.42 0.19 / 0.03 0.846
Pathology  (AHS /  Rasmussen’s encephalitis + le-
sion associated) 0.43 / 0.28 0.04 / 0.04 0.114
D) Clinical data of mTLE patients: correlation to gene expression of GABRB3
Clinical variables Mean SEM P
Gender (Male / Female) 0.16 / 0.16 0.01 / 0.01 0.644
Depression (yes / no) 0.14 /0.17 0.02 / 0.01 0.145
Number of Seizures per month  (0-10 / 11- more 
than 100) 0.16 / 0.15 0.01 / 0.01 0.735
Seizure-free post-operative (I A +II B/ I B + IV B) 0.16 / 0.17 0.01 / 0.01 0.531
Age at seizure onset in years (1-10 / 11-50) 0.16 / 0.16 0.01 / 0.01 0.716
Age at epilepsy surgery in years (1-10 / 11-64) 0.16 / 0.16 0.02 / 0.01 0.891
Pathology  (AHS /  Rasmussen’s encephalitis + le-
sion associated) 0.16 / 0.19 0.01 / 0.03 0.158
Pernhorst et al., Supplemental Table 4, Supplemental Digital Content 5:
Analysis of antiepileptic and antidepressant drug effects on gene expression of 
candidate genes and examination of antiepileptic drug treatment frequency in 
depressive patients.
A,  B) The relative gene expression of candidate genes is given in patient groups 
stratified  according  to  administration  of  distinct  antiepileptic  drugs  with  potential 
general effects on transcription, i.e. topiramate, valproic acid and levetiracetam. No 
significant  differences in expression of ALDH5A1 or GABRB3 were  present.  Also 
antidepressants  including  Citalopram,  Escitalopram,  Haloperidol,  Fluoxetine, 
Mirtazapine,  Risperidone, Venlafaxine,  Sertraline, Olanzapine and Amisulpride did 
not show effects on gene expression of both genes. Relative gene expression values 
are given  as mean ± SEM. A two-tailed t-test was applied.  C) Several antiepileptic 
compounds  can  result  in  mood  disturbances.  In  order  to  analyze  for  respective 
effects  of  pharmacotherapy  in  the  present  patients,  we  analyzed  potential 
overrepresentation  of  pharmacotreatment  with  topiramate,  valproic  acid  and 
levetiracetam in patients with depression. However, depression was not significantly 
more frequent in patients treated with these antiepileptic compounds compared to 
individuals not receiving respective compounds.
A) Antiepileptic/antidepressant drug therapy: correlation to gene 
expression of ALDH5A1
Antiepileptic drug Number of pati-ents Mean SEM P
Topiramat (yes / no) 3 / 34 0.30 / 0.42 0.04 / 0.03 0.288
Valproic acid (yes / no) 4 / 33 0.30 / 0.43 0.07 / 0.03 0.233
Levetiracetam (yes / no)
8 / 29
0.49 / 0.39 0.07 / 0.04 0.224
Antidepressants (yes / no)
6 / 31
0.39 / 0.42 0.08 / 0.04 0.755
B) Antiepileptic/antidepressant drug therapy: correlation to gene 
expression of GABRB3
Antiepileptic drug Number of pati-ents Mean SEM P
Topiramat (yes / no) 5 / 51 0.18 / 0.16 0.02 / 0.01 0.497
Valproic acid (yes / no) 8 / 48 0.14 / 0.16 0.01 / 0.01 0.413
Levetiracetam (yes / no)
21 / 36
0.16 / 0.16 0.01 / 0.01 0.765
Antidepressants (yes / no)
7 / 49
0.14 / 0.16 0.02 / 0.01 0.345
C) Antiepileptic drug therapy: correlation to depression
Depression
Χ2 P
+ -
Number of patients 87 112
Antiepileptic drug Topiramat 10 9 0.26 0.61
Valproic acid 12 29 2.36 0.124
Levetiracetam 49 48 0.95 0.329
3. Pernhorst et al., Neuropathol Exp Neurol, 2011
3.3 Summary
Human GABRB3 and ALDH5A1 genes encode for proteins both involved in GABA
homeostasis. The GABRB3 gene codes for a chloride channel subunit that serves as
receptor for GABA. Downstream in the catabolism pathway of GABA, the ALDH5A1
gene codes for succinic semialdehyde dehydrogenase (SSADH) that catalyzes an impor-
tant step in the degradation of GABA. The inhibitory neurotransmitter GABA acts
as essential regulator of excitability of neuronal networks (Mody and Pearce, 2004).
In this project, we focused on the question, how promoter variants impair stimulus-
induced GABA homeostasis relevant gene expression. We concentrated on analyses of
the promoter SNPs rs1883415 and rs4906902 in surgical brain tissue from patients with
epilepsy. We further explored the potential influence of such genetic variants on the
binding affinity of regulating TFs.
GABRB3 as well as ALDH5A1 mRNA expression levels exhibit prominent differences
correlating to the presence of respective SNP genotypes. Thus, GABRB3 mRNA ex-
pression levels are significantly higher in brain tissue from TLE patients with the AA
genotype compared to patients harboring the genotype GG of the SNP rs4906902. The
same holds true for ALDH5A1 mRNA expression. The group of TLE patients carry-
ing the genotype AA of the SNP rs1883415 shows a significantly lower gene expression
compared to the group of TLE patients homozygous for the C allele. Subsequently, we
bioinformatically determined potential TFBSs at relevant SNP positions in order to
uncover changes of TF binding affinity dependent on the respective SNP and their im-
pact on the differential regulation of gene expression. The resulting data suggest that
promoter SNPs affect the binding affinity of candidate TFs. In the promoter region of
GABRB3, the activating TF Myocyte enhancer factor 2 (MEF-2) shows a higher bind-
ing affinity to the target sequence carrying the A allele than to the G allele sequence.
In the case of ALDH5A1, we detected a potential binding site for the activating TF
Early growth response 3 (Egr-3) with higher binding affinity to the C sequence variant
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compared to the A sequence variant. In luciferase assays MEF-2 activated the A allele
promoter variant significantly stronger than the G allele promoter variant. Concerning
the bioinformatically predicted Egr-3 binding site in the ALDH5A1 promoter, the ex-
posure of Egr-3 to both promoter variants lead to a substantially increased promoter
activation in the case of the C allele. Therefore, our results indicate that SNPs affect
promoter activity by altering binding affinity of TFs.
Our data suggest that in human TLE, aberrant expression of genes coding for GABA-
receptor subunits such as GABRB3 as well as GABA-degrading enzymes such as
ALDH5A1 may result in an impairment of GABA metabolism and therefore disturb
neurotransmission in affected brain tissue. Our data indicate the significance of pro-
moter variants for the regulation of gene expression based on human brain tissue of
patients with neurological brain disorders.
In addition to genes involved in GABA-mediated signaling, multiple studies revealed an
evidence for promoter variants in genes known to be associated with hyperexcitability.
Former studies point to a role of impaired serotonergic neurotransmission in facilitating
seizure onset and inducing seizure severity (Lesch, 2001; Savic et al., 2004). Hence,
the study of regulatory allelic variants affecting transcriptional changes in serotonin
homeostasis-related genes, reveals an interesting aspect to investigate mechanisms in
disorders characterized by episodic persistent onset of symptoms.
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4 Rs6295 promoter variants of the serotonin type
1A receptor are differentially activated by c-Jun
in vitro and correlate to transcript levels in hu-
man epileptic brain tissue
4.1 Introduction
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a main neurotransmitter in
the CNS. In the case of epilepsy, serotonin was described to have an impact on seizure
development, propagation and maintenance (Berumen et al., 2012). In addition, it
was reported that an imbalance of serotonin levels is accompanied by both depressive
symptoms and increased aggression (Siever, 2008; Kishi et al., 2009).
In general, released from serotonergic neurons in the raphe nucleus, serotonin activates
G protein-coupled 5-HT receptors (5HT1ARs) located on the membrane of pyramidal
and granular neurons (Wisden, 2010). 5HT1AR represents the most common subtype
of seven classes of 5-HT receptors in the hippocampus. It plays a role in presynap-
tic as well as in postsynaptic signal transduction (Chaput et al., 1986; Hoyer et al.,
1994, 2002). Animal studies using knockout mice lacking 5HT1AR revealed enhanced
anxiety-related behavior (Gardier, 2009; Saxena and Chattopadhyay, 2011). Respective
animals show a lower seizure threshold as well as an increased seizure activity, indicat-
ing 5HT1AR to be involved in neuronal excitability (Sarnyai et al., 2000). Likewise,
selective inhibitors of serotonin uptake showed anticonvulsant effects both in experi-
mental rat models (Pasini et al., 1992) and humans (Favale et al., 1995). Favale et
al. suggest that the antiepileptic action of these inhibitors of serotonin uptake leads
to anticonvulsant effects by potentiating serotonergic activity (Favale et al., 2003).
Therefore, impairment of serotonergic homeostasis may play a role in the pathogenesis
of neurological disorders including epilepsy.
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The promoter region of the 5HT1AR encoding gene HTR1a comprises the SNP rs6295.
This specific SNP has been associated with several CNS disorders including epilepsy,
migraine and depression (Lemonde et al., 2003; Marziniak et al., 2007; Francois et al.,
2008). Additionally, it has been further shown that the GG genotype of SNP rs6295 is
related to the avoidance of physical activity during migraine attacks and that the SNP
constitutes a risk factor for depression (Marziniak et al., 2007; Francois et al., 2008).
The underlying mechanism was suggested to be an increase of 5-HT1A autoreceptor lev-
els accompanied by reduced serotonin neurotransmission (Albert and Lemonde, 2004).
Further, it was proposed that the SNP rs6295 modulates the response to antidepressant
and antipsychotic treatment (Francois et al., 2008). However, the distinct effect of SNP
variants on gene expression remained unclear. Based on human hippocampal tissue,
we want to investigate the functional relevance of SNP rs6295 for HTR1a expression
as well as for binding affinity of transcriptional regulators. Therefore, we performed
comprehensive bioinformatic, molecular genetic and in vitro approaches.
The subsequent manuscript published in January 2013 in Brain Research is allowed by
Elsevier Journals to be include in a thesis or dissertation with full acknowledgment of
the final article.
My contribution to this work covers the preparation of 140 human hippocampal brain
tissue samples derived from pharmacoresistant TLE patients, DNA and mRNA isola-
tion, the genotyping of samples dependent on SNP rs6295 using TaqMan SNP Geno-
typing Assay and real-time RT-PCR experiments comparing sample groups according
to their SNP rs6295 genotype. Additionally, I generated the reporter plasmid con-
structs for transient transfections in cell culture and subsequently performed luciferase
assay experiments in order to clarify the in silico prediction of potential TFBSs as well
as Chromatin immunoprecipitation assay (ChIP) assays to verify the binding of c-Jun
to HTR1a promoter. These also included the bioinformatic and statistical analyses
and the writing of the manuscript.
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Many brain disorders, including epilepsy, migraine and depression, manifest with episodic
symptoms that may last for various time intervals. Transient alterations of neuronal
function such as related to serotonin homeostasis generally underlie this phenomenon.
Several nucleotide polymorphisms (SNPs) in gene promoters associated with these
diseases have been described. For obvious reasons, their regulatory roles on gene
expression particularly in human brain tissue remain largely enigmatic. The rs6295 G-/
C-allelic variant is located in the promoter region of the human HTR1a gene, encoding the
G-protein-coupled receptor for 5-hydroxytryptamine (5HT1AR). In addition to reported
transcriptional repressor binding, our bioinformatic analyses predicted a reduced binding
affinity of the transcription factor (TF) c-Jun for the G-allele. In vitro luciferase transfection
assays revealed c-Jun to (a) activate the rs6295 C- significantly stronger than the G-allelic
variant and (b) antagonize efficiently the repressive effect of Hes5 on the promoter. The G-
allele of rs6295 is known to be associated with aspects of major depression and migraine.
In order to address a potential role of rs6295 variants in human brain tissue, we have
isolated DNA and mRNA from fresh frozen hippocampal tissue of pharmacoresistant
temporal lobe epilepsy (TLE) patients (n¼140) after epilepsy surgery for seizure control. We
carried out SNP genotyping studies and mRNA analyses in order to determine HTR1a
mRNA expression in human hippocampal samples stratified according to the rs6295 allelic
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variant. The mRNA expression of HTR1a was significantly more abundant in hippocampal
mRNA of TLE patients homozygous for the rs6295 C-allele as compared to those with the
GG-genotype. These data may point to a novel, i.e., rs6295 allelic variant and c-Jun
dependent transcriptional 5HT1AR ‘receptoropathy’.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Impaired serotonin homeostasis is a frequent pathogenetic
aspect in many neuropsychiatric disorders including depres-
sion, migraine and epilepsy (Trindade-Filho et al., 2008;
Bahremand et al., 2011; Richerson and Buchanan, 2011;
Theodore et al., 2012). The episodic, sustained onset of
symptoms in these disorders suggests transient alterations
of serotonin signaling due to factors such as transcriptional
changes of relevant receptors (Lambru and Matharu, 2011;
Richerson and Buchanan, 2011; Theodore et al., 2012). The
serotonin-1A receptor (5HT1AR) is a central component in
activity regulation of the serotonin system, and is expressed
in many neuronal structures including the hippocampus
where it serves as major postsynaptic receptor of neurons
(Le Francois et al., 2008). Association studies suggest that
genetic variation of the HTR1a gene influences the risk for a
broad range of neuropsychiatric disorders (Lemonde et al.,
2003; Marziniak et al., 2007; Le Francois et al., 2008). Lack of
common missense variations in the HTR1a gene may suggest
that regulatory sequence variations affecting gene expression
of the HTR1a gene exert the functional effects.
Here, we have investigated the functional role of the single
nucleotide polymorphism (SNP) rs6295 located in the promo-
ter of HTR1a for the expression of the respective gene in
human brain tissue. Rs6295 shows prominent associations in
several neuropsychiatric disorders. In migraineurs, the rs6295
GG-genotype is associated with avoidance of physical activity
during migraine attacks (Marziniak et al., 2007). The G-allele
of rs6295 is linked to major depression, panic disorders and
neuroticism (Lemonde et al., 2003; Le Francois et al., 2008).
The G-allele of rs6295 is further related to reduced response
to antidepressant or antipsychotic treatment (Le Francois
et al., 2008). Rs6295 has been demonstrated as a functional
promoter variant affecting binding sites for transcriptional
repressors such as NUDR/Deaf1 and Hes5 (Albert et al., 2011).
Yeast one-hybrid analyses suggested repression of the HTR1a
promoter activity by NUDR and Hes5 preferentially at the
rs6295 C-allele (Lemonde et al., 2003). These data implied that
the rs6295 G-allele mediates a reduced repression of the
HTR1a promoter, which leads to higher HTR1a mRNA levels
in brain tissue and thereby increases individual risk of
neuropsychiatric disorders.
However, SNPs can have ambiguous roles for transcription
factor binding. We have therefore used bioinformatic promo-
ter analysis in order to find transcriptional activator binding
affected by the rs6295 variants. Based on respective results,
we have analyzed a potential functional role of the transcrip-
tional activator c-Jun on rs6295 in vitro. Given the association
of rs6295 with episodic brain disorders and the in vitro
evidence for an allele-specific regulation of the HTR1a pro-
moter activity, we have subsequently explored whether the
rs6295 alleles influence HTR1a mRNA expression in human
brain tissue. Therefore, we used our unique access to fresh
frozen hippocampal tissue of temporal lobe epilepsy (TLE)
patients that underwent epilepsy surgery for seizure control.
A previous association study did not support a risk-
conferring effect of the HTR1a promoter SNP rs6295 in TLE
(Stefulj et al., 2010). Due to the high number of neuropsy-
chiatric co-morbidities in TLE, we further addressed potential
clinico-genetic associations of rs6295 in TLE patients as
addressed in a previous study in our present TLE patient
series (Theodore et al., 2012).
2. Results
2.1. Bioinformatic promoter analysis reveals a c-Jun
binding site at rs6295 with allele specific binding affinities
We have used bioinformatic promoter analysis in order to
find transcriptional activator binding affected by the rs6295
variants. We predicted the position and conservation of a
putative binding site for c-Jun using position-specific-scoring
matrices in the HTR1a promoter region (Fig. 1A). The rs6295
C-variant exhibits a potential c-Jun binding motif with a
higher ‘motif similarity score’, i.e., binding affinity compared
to an ‘ideal’ binding motif, compared to the c-Jun binding
motif in the G-variant (73% vs. 65%; Fig. 1A and B). Using
chromatin immunoprecipitation (ChIP) assays, we observed
substantial binding of c-Jun at the HTR1a promoter on protein
level (Student’s t-test: p¼0.0025; n¼14; Fig. 1C–D).
2.2. c-Jun exposure results in stronger activation of the
rs6295 C-allelic than G-allelic variant
We next addressed the biological impact of this bioinformatic
prediction by using luciferase reporter constructs including
different promoter variants of HTR1a at the rs6295 site
(Supplemental Fig. 1). In a first experiment, we addressed
the basal HTR1a promoter activity for the both rs6295 var-
iants. This activity was not significantly different for the
rs6295 C-allelic versus the G-allelic variant (Student’s t-test:
p¼0.081; n¼4 each; Fig. 1E). Increased levels of c-Jun strongly
activate both HTR1a promoter variants compared to respec-
tive unstimulated controls (C-allele: one-way ANOVA:
po0.001; G-allele: one-way ANOVA: po0.05; n¼4 each;
20 ng c-Jun; Fig. 2A). Our data furthermore demonstrate that
the transcription factor c-Jun activates the rs6295 C-allelic
variant significantly stronger than the rs6295 G-allele (one-
way ANOVA: po0.05; 20 ng c-Jun; Fig. 2A). Intriguingly, the
expression levels of c-Jun in hippocampi of TLE patients
included in the present series harboring the rs6295 C-allele
are higher compared to c-Jun expression in individuals
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homozygous for the rs6295 G-allele (Student’s t-test:
p¼0.039; Fig. 4C). The previously reported transcriptional
repressors NUDR and Hes5 were analyzed by adding 10 ng of
each transcriptional repressor. Thereby, we observed a sig-
nificant inhibition of HTR1a promoter activity by NUDR for
both genotypes (C-allele: Student’s t-test: p¼2108;
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Fig. 1 – Bioinformatic analysis of TF-binding site modifications in the HTR1a promoter. (A) The promoter of the HTR1a gene
comprises the rs6295 SNP 1019 bp upstream of transcriptional start ‘ATG’. We identified a putative binding site for the
activating transcription factor c-Jun in the C-sequence with a binding affinity of 73%. In the G-variant of the HTR1a promoter
sequence, the predicted binding affinity of this TF-binding site is 65%. (B) The predicted c-Jun binding motif in the HTR1a
promoter region is represented at each position with the corresponding matrix similarity score (MSS) as a percentage.
In the consensus motif of c-Jun, the size of each nucleotide denotes the frequency of the nucleotide at this position.
(C) A representative PCR analysis of ChIP products shows the binding of c-Jun to the HTR1a promoter. (D) Quantification of the
ChIP experiment demonstrates a significant binding of c-Jun to the HTR1a promoter compared to the basal promoter
(Student’s t-test: p¼0.0025; n¼14). (E) The basal luciferase activity of the CC-(black bar) and GG-promoter fragments
(white bar) of HTR1a did not differ significantly (Student’s t-test: p¼0.081; n¼4 each).
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Fig. 2 – In vitro luciferase activity analysis of HTR1a promoter variants. (A) Adding 10 ng of the transcriptional repressor NUDR leads
to a significant inhibition of HTR1a promoter activity for both genotypes (C-allele: Student’s t-test: p¼2108; n¼4 each; white
bars; G-allele: Student’s t-test: p¼3107; n¼4 each; black bars). The same holds true for the transcriptional repressor Hes5
(C-allele: Student’s t-test: p¼0.037; n¼4 each; white bars; G-allele: Student’s t-test: p¼4105; n¼4 each; black bars). There is a
stronger repressing effect of Hes5 on the promoter G-variant compared to the C-variant (one way ANOVA: po0.001; n¼4). Both
promoter fragments homozygous for the G- and C-alleles are significantly activated after overexpression of c-Jun (20 ng) compared
to basal states (C-allele: one-way ANOVA: po0.001; n¼4 each; white bars; G-allele: one-way ANOVA: po0.05; n¼4 each; black
bars). Intriguingly, there is a substantially stronger activation of the promoter fragment carrying the rs6295 C-allele (white bar)
compared to the G-allele (black bar) after exposure of both HTR1a promoters with 20 ng c-Jun (one-way ANOVA: po0.05; n¼4
each). (B) Exposure of only 10 ng NUDR and increasing concentrations of c-Jun in combination with 10 ng of the transcriptional
repressor NUDR to both genotypes leads to a significant decrease in promoter activity compared to basal level (one-way ANOVA:
po0.001; n¼4). After combined overexpression of c-Jun (10 ng) and NUDR (10 ng), the HTR1a promoter activity is significantly
increased compared to overexpression of NUDR alone in the CC-genotype (one-way ANOVA: po0.05; n¼4 each; white bars).
(C) For both the C- and the G-variant, the HTR1a promoter is significantly repressed after exposure to Hes5 alone compared to
basal level (one-way ANOVA: po0.05; po0.001; n¼4 each). The HTR1a promoter activity is significantly increased when
simultaneously adding c-Jun and Hes5 (10 ng each) for the C-variant and after exposure of combined Hes5 (10 ng) with
increasing concentration of c-Jun for the G-variant compared to overexpression of Hes5 alone (one-way ANOVA: po0.01;
po0.001; n¼4 each). For the C-variant only the combined overexpression of c-Jun and Hes5 showed a reversible effect by
adding c-Jun. The comparison of the HTR1a promoter activity after overexpression with Hes5 and c-Jun (10 ng each) showed a
significantly stronger effect for the promoter fragment homozygous for the C-allele (one-way ANOVA: po0.01; n¼4 each).
G-allele: Student’s t-test: p¼3107; n¼4 each; Fig. 2A).
The same holds true for the transcriptional repressor Hes5
(C-allele: Student’s t-test: p¼0.037; G-allele: Student’s t-test:
p¼4105; n¼4 each; Fig. 2A). To address the question
whether the inhibitory effects of the transcriptional repres-
sors NUDR and Hes5 are antagonized by the activating TF c-
Jun, we performed in vitro luciferase assays where we
exposed the respective promoter to combinations of either
NUDR or Hes5 with c-Jun. After combined overexpression of
c-Jun (10 ng) and NUDR (10 ng), the HTR1a promoter activity is
significantly increased compared to overexpression of only
NUDR (10 ng) in the CC-genotype, even though the absolute
differences of promoter activation are not very large (one-
way ANOVA: po0.05; n¼4 each; Fig. 2B). For the CC- as well
as the GG-genotype the combined overexpression of c-Jun
and Hes5 showed a significant repressor-antagonizing effect
of c-Jun (one-way ANOVA: po0.01; n¼4 each; Fig. 2C).
Interestingly, the comparison of the HTR1a promoter activity
after overexpression with Hes5 and c-Jun (10 ng each) showed
a significantly stronger effect for the promoter fragment
homozygous for the rs6295 C-allele than for the G-allele
(one-way ANOVA: po0.01; n¼4 each; Fig. 2C).
2.3. Different HTR1a expression levels in human
hippocampal mRNA of individuals homozygous
for the rs6295 C- versus G-allele
Human hippocampal biopsy samples derived from epilepsy
surgery for seizure control of pharmacoresistant TLE patients
represent a unique resource of human brain tissue for
molecular analyses (Fig. 3A). In order to examine potentially
differential allele-specific expression levels, we compared
HTR1a mRNA expression in the brain tissue samples of TLE
patients homozygous for the rs6295 C-allele (C/C; n¼23) with
transcript levels of patients homozygous for the G-allele (G/G;
n¼20). The relative gene expression of HTR1a was 2.2-fold
significantly higher in hippocampi of TLE patients homozy-
gous for the rs6295 C-allele compared to those homozygous
for the G-allele (Student’s t-test: p¼0.013; Fig. 3B). Addition-
ally, the TLE patients homozygous for the C-allele compared
to patients harboring the rs6295 CG-genotype demonstrated a
significantly higher mRNA expression level for HTR1a (CC vs.
CG: one-way ANOVA; po0.05; Supplemental Fig. 2). Compar-
ing transcript levels of patients with the rs6295 CG-genotype
to patients homozygous for G-allele revealed no significant
difference of respective mRNA expression.
2.4. Clinical parameters of TLE patients do not correlate
with the allelic variants of rs6295 or HTR1a mRNA
expression
With respect to the reported associations of distinct rs6295
genotypes with several neuropsychiatric disorders, we car-
ried out a comprehensive co-variance analysis of clinical,
therapeutic and co-morbidity data of the patients included
here (Supplemental Tables 1–4). These analyses did not result
in significant associations of particular rs6295 genotypes or
HTR1a mRNA expression with any of the individual para-
meters investigated. Therefore, the significant differences
in HTR1a transcript levels in individuals homozygous for the
C- versus G-alleles of rs6295 point to a substantial allele-
specific effect on promoter activity in human brain tissue.
2.5. Transcriptional repressors differentially binding
rs6295 allelic variants are equally expressed in human
hippocampal mRNA of individuals homozygous for
the C- versus G-alleles
It was previously demonstrated by others that the transcrip-
tional repressors NUDR and Hes5 have a higher binding
affinity to the rs6295 C-allele of the HTR1a promoter
(Lemonde et al., 2003; Albert et al., 2011). Therefore, our
finding of a higher HTR1a mRNA expression level in hippo-
campi of TLE patients carrying the CC- genotype was unex-
pected and seemed potentially contradictory to our initial
hypothesis. In a next step, we analyzed the mRNA expression
of respective transcriptional repressors in human hippocam-
pal mRNA of our TLE patients. We did, however, not observe
differential expression of the transcriptional repressors
NUDR and Hes5 in individuals homozygous for the different
rs6295 alleles (Fig. 4A and B), which would have provided a
potential explanation for our initial observation of differen-
tial HTR1a mRNA levels in individuals homozygous for the
C- versus G-alleles of rs6295. Unfortunately, control human
hippocampal tissue was not available for further mRNA
expression analyses.
3. Discussion
Our present results suggest that the transcription factor c-Jun
has significantly different activating effects on rs6295 SNP
promoter HTR1a variants, i.e., c-Jun binds in vivo to the HTR1a
promoter and more strongly activates the C-variant (Fig. 1A
and B). Furthermore, we confirmed the previously reported
repressing effects of NUDR and Hes5 on the promoter
(Lemonde et al., 2003; Albert et al., 2011). Our own bioinfor-
matic TF binding site analyses at rs6295 for NUDR (C-allele:
61% and G-allele: 60%) and Hes5 (C-allele: 56.6% and G-allele:
46.6%) as well as the luciferase assays suggest, however,
a stronger repressive effect for Hes5 for the rs6295 SNP
G-variant (Fig. 2C). Our data demonstrate that rs6295 is
located in an effective binding site for transcriptional repres-
sors as well as activators in the HTR1a promoter. In this
context, rs6295 has significant effects on the promoter
activity modulation by respective transcriptional repressors
and activators. How do these effects interfere? In the case of
NUDR, although there is a statistically significant antagonis-
tic effect on repression by c-Jun on the C-variant promoter,
the effect size appears biologically not prominent (Fig. 2B).
Intriguingly, c-Jun has the potency of strongly antagonizing
the inhibitory effect of Hes5 in both promoter variants
(Fig. 2C). However, there is significantly stronger HTR1a
promoter activity in the case of exposure to Hes5 and c-Jun
for the rs6295 C- instead of G-variant. This result may be due
to additive functions by (a) the stronger activating effect of c-
Jun and (b) the attenuated repressive effect of Hes5 on the C-
variant. Whereas for NUDR, its repressive effect on the
promoter is strongly evident independent of the presence of
c-Jun in both SNP variants, Hes5 and c-Jun in similar
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concentrations virtually neutralize each other’s effects in the
HTR1a promoter (Fig. 2C).
Certainly, it can only be speculated on respective effects
and interplay of the repressors and c-Jun in vivo in depres-
sion and migraine, since respective tissue samples for quan-
tification of transcriptional repressors and activators as well
as promoter binding studies are not available. Some of these
limitations can be overcome in hippocampal tissue of TLE
patients. More abundant HTR1a mRNA was present in indivi-
duals with the rs6295 CC-genotype compared to patients with
the GG-genotype. However, for transcript analyses in true
human control hippocampi the obvious lack of respective
tissue samples remains an obstacle. Furthermore, it cannot
entirely be resolved how acute and dynamic expression
alterations of the transcriptional repressors and c-Jun depen-
dent on seizure activity in patients affect expression levels of
HTR1a.
Intriguingly, c-Jun expression levels are higher in hippo-
campal mRNA of TLE patients with the rs6295 CC-genotype
compared to those with the GG-genotype. The cause of the
latter observation is not clear. However both factors, i.e.,
stronger HTR1a promoter activation of the rs6295 C-allele and
higher expression levels of c-Jun in hippocampal tissue of
respective individuals should be independent factors adding
up in a functional fashion with respect to expression of
HTR1a. Although in luciferase assays, there is no different
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Fig. 3 – HTR1a mRNA expression in human hippocampal tissue. (A) A representative section of a bioptic human hippocampal
specimen of a pharmacoresistant TLE patient after selective amygdalahippocampectomy shows the characteristics of
hippocampal sclerosis (HS) with reduced neuronal densities particularly in CA1 and CA3/4 and concomitant astrogliosis
(hematoxylin & eosin staining; grey asterisk—dentate gyrus (DG) granule cell layer; black asterisk—CA4; white
asterisk—CA2; black arrows—CA1; bar graph—2.0 mm), i.e., containing major CNS cell populations. (B) The relative mRNA
expression of HTR1a is significantly increased in the group of TLE patients homozygous for the rs6295 C-allele (n¼23;
0.1670.03; black bar) compared to the group carrying the GG genotype (n¼20; 0.0770.01; Student’s t-test: p¼0.013;
white bar).
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basal activity of the rs6295 CC- compared GG-promoter
variants, the situation with respect to dynamics of the
transcription factor environment may be even more complex
and different in human hippocampal tissue. c-Jun expression
and the rs6295 genotypes in human hippcampal tissue in this
context did not co-vary with respect to HTR1a transcript
levels (data not shown). In status epilepticus animal models,
increased hippocampal expression of c-Jun has been reported
(Han et al., 2009). The hippocampal expression levels of c-Jun
after chronic spontaneous seizure activity is difficult to
determine. In the chronic stage after status epilepticus,
animals are desynchronized with respect to seizure activity
and c-Jun is extremely variable in mRNA expression after
episodic insults such as spontaneous seizures. However, we
speculate that there is increase of c-Jun as an immediate
early gene after seizure activity.
Our data suggest that in addition to previously reported
transcriptional repressors, the activating TF c-Jun as a promi-
nent immediate early gene has a substantial impact on
mRNA expression levels of HTR1a in human epileptic brain
tissue. However, our findings clearly relate to the situation of
TLE. For TLE, the present data suggest a scenario in which
putatively transiently increased expression levels of c-Jun,
e.g. in the context of enhanced neuronal activity levels
(Sheng and Greenberg, 1990) substantially alter the expres-
sion of HTR1a in individuals harboring the C-allele of rs6295
compared to basal states. This effect presumably leads to
impaired serotonin homeostasis. Our data in human TLE
does not allow direct extrapolation onto other neuropsychia-
tric disorders such as depression and migraine since the
expression levels of relevant transcriptional repressors and
activators may be entirely different in these disease contexts.
However, our data suggest that the modulatory effect of
transcription factor binding at rs6295 is not restricted to
repressor proteins.
In TLE, however, our data propose substantial effects of
the rs6295 genotype mediated by c-Jun on HTR1a expression.
Whether this data points to a novel form of a transcriptional
acquired 5HT1AR ‘receptoropathy’ needs to be clarified by
future, e.g., electrophysiological and animal model functional
approaches.
4. Experimental procedure
4.1. Patient criteria and surgical specimens
We included hippocampal biopsy specimens of 140 pharma-
coresistant TLE patients. The ascertainment scheme and
clinical characteristics have been described in detail pre-
viously (Kral et al., 2002; Pernhorst et al., 2011) (Fig. 3A).
Informed written approval was obtained from all patients
and procedures were in accordance with the Declaration of
Helsinki and approved by the local ethics committee. Depres-
sive symptoms of patients were assessed according to Beck
Depression Inventory (BDI; threshold BDI Z12) (Beck et al.,
1961). Anxiety and aggression scores were determined by a
standardized questionnaire (Helmstaedter, 2001). Epilepsy-
free controls for association studies belong to the cardiovas-
cular longitudinal Heinz-Nixdorf-Recall study (HNR cohort;
Schmermund et al., 2002).
4.2. Sample preparation
Processing of tissue, DNA and mRNA isolation, cDNA pre-
paration and real time RT-PCR were carried out as described
before (Pernhorst et al., 2011).
4.3. SNP Genotyping analysis and real time RT-PCR
Genotyping of SNP rs6295 was performed using a TaqMan
SNP Genotyping Assay (HTR1a: C__11904666_10; Applied
Biosystems, Foster City, CA, USA). The assignment of the
alleles of the SNP rs6295 refer to the forward genome strand
orientation relative to the NCBI reference genome build 36.
Analysis of HTR1a mRNA expression was carried out as
described before in detail (Pernhorst et al., 2011) (TaqMan
Gene Expression Assay (HTR1a: Hs00265014_s1; Applied
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Fig. 4 – The mRNA expression of transcriptional repressors and activating TFs. (A) The relative mRNA expression for the
transcriptional repressor NUDR in rs6295 CC-genotype patients (n¼17; 0.04370.003; black bar) differs not significantly
compared to GG-genotypes patients (n¼16; 0.04870.004; Student’s t-test: p¼0.285; white bar). (B) The same holds true for
the transcriptional repressor Hes5 in patients with the CC-genotype (n¼17; 0.01970.002; black bar) compared to GG-
genotype TLE individuals (n¼16; 0.01870.003; Student’s t-test: p¼0.768; white bar). (C) c-Jun expression in patients with the
rs6295 CC-genotype (n¼17; 0.12370.016; black bar) is significantly higher compared to patients homozygous for the rs6295
G allele (n¼16; 0.08270.009; Student’s t-test: p¼0.039; white bar).
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Biosystems, Foster City, CA, USA). ß-actin was used as
endogenous reference gene for normalization of the analyzed
mRNAs.
4.4. Sample preparation and microarray analysis
Total RNA for gene expression microarray analysis was
isolated from human hippocampal tissue samples using
AllPrep DNA/RNA Mini Kit (Qiagen, Hilden) according manu-
facturer’s protocol. In order to synthesize cDNA from total
RNA and in vitro transcription to biotin-labeled cRNA, Illu-
mina TotalPrep-96 RNA Amplification Kit (Life Technologies
Corporation, Darmstadt) was used according to the manu-
facturer’s protocol. For analysis of c-Jun mRNA expression,
cRNA was then hybridized on HumanHT-12 v3 Expression
BeadChips using lllumina Direct Hybridization Assay Kit (Life
Technologies Corporation, Darmstadt, Germany). The Illu-
mina BeadArray Reader was applied for scanning and
resulted data was analyzed using Illumina’s GenomeStudio
Gene Expression Module. Gene expression data were normal-
ized using the Illumina BeadStudio software suite by means
of quantile normalization with background subtraction.
4.5. Reporter plasmids
The HTR1a-luciferase reporter plasmid was constructed by
cloning a 1102bp fragment of the human HTR1a promoter
harboring the SNP rs6295 that was amplified by PCR using
human genomic DNA as template (Fwd-primer 50-CTC GAG
TGT TGT TGT CGT CGT TGT TC-30, Rev-primer 50-AGA TCT
GGA AGG GGG AGG GAA GA-30) and digested with XhoI and
BglII into the luciferase reporter construct, pGL-3 basic (Pro-
mega Biotech, Madison, WI) (Supplemental Fig. 1).
4.6. Transient transfections
NG108-15 neuroblastoma cells were plated at a density of 80%
confluency in 48-well plates and grown in 0.5 ml of DMEM
supplemented with 10% v/v fetal calf serum, 5% Pen Strep
and 5% HAT. Transfection of the cells was carried out using
lipofectamine (Invitrogen, Darmstadt, Germany) following
the manufacturer’s protocol. For each well of the 48-well
tissue culture plate, 50 ng luciferase reporter plasmid, 12.5 ng
pRL-TK and 0.5 ml lipofectamine were mixed with 12.5 ml
medium. Different amounts of a previously described vector
containing a c-Jun expression sequence were used in respec-
tive experimental assays (Leppa et al., 1998). 10 ng of each
repressing overexpression plasmid Hes5 (Nakashima et al.,
2001) and NUDR (Michelson et al., 1999) were used. All
mixtures were incubated for 20 min at room temperature
and then added to the appropriate wells. Cells were grown in
culture medium for 6–12 h at 37 1C and 5% CO2. Thereafter,
the medium was replaced by fresh medium and the cells
were used for experiments 48 h after transfection.
4.7. Luciferase assays
Renilla luciferase was used to normalize the transfection
efficiency data, and a Dual Luciferase Reporter Assay System
was used according to the manufacturer’s specifications
(Promega, Biotech, Madison, WI). Renilla and firefly luciferase
activities were determined using the Glomax Luminometer
(Promega, Biotech, Madison, WI), counting each sample four
times. The results are given as Firefly/Renilla relative light
units if not indicated otherwise.
4.8. Chromatin immunoprecipitation (ChIP) assays
NG108-15 neuroblastoma cells (6-wells; 80% confluency) were
transfected with pCMV-cJun or the empty pCMV vector using
lipofectamine (Invitrogen, Darmstadt, Germany). The cells
were crosslinked with 1% formaldehyde for 10 min at 37 1C
48 h after transfection followed by two washing steps in ice-
cold PBS containing protease inhibitors (PIs; Roche Applied
Science, Indianapolis, IN). The cells were collected, centri-
fuged and lysed in SDS lysis buffer (1% SDS; 10 mM EDTA;
50 mM Tris, pH 8.1 with PIs). An incubation step for 10 min on
ice was attached. The ChIP sample processing has been
described in detail elsewhere (van Loo et al., 2012). After
phenol/chloroform extraction, the resulted DNA was ana-
lyzed by PCR using primers detecting the HTR1a promoter
region: HTR1a_c-Jun_CHIP_FW: 50-TGT CGT CGT TGT TCG
TTT GT-30; HTR1a_c-Jun_CHIP_REV: 50-GGT GAA CAG TCC
TGG GTC AG-30; HTR1a_control_CHIP_FW: 50-CCA GGT GCT
GAA CCC AGT TT-30; HTR1a_control_CHIP_REV: 50–CAT GGC
CTT TTG CAC TTC TT-30. The following PCR was performed
using following conditions: 94 1C for 3 min, then 35 cycles of
45 s at 94 1C, 30 s at 60 1C, 1 min at 72 1C, followed by a final
extension step at 72 1C for 10 min. The PCR products were
analyzed on 1.5% agarose gel and quantified using AIDA
software.
4.9. Bioinformatic analyses
For identification of the potential promoter region upstream
of the HTR1a gene, the web tools and software tools CpGPlot
(Rice et al., 2000), Promoter2.0 (Knudsen, 1999), COMET (Frith
et al., 2002) and Eponine (Down and Hubbard, 2002) were
applied. To identify the position and conservation of potential
transcription factor binding sites, PoSSuMsearch (Beckstette
et al., 2006) using position-specific-scoring matrices (PSSMs)
from the TRANSFAC database was applied to the potential
promoter region. For filtering the potential transcription
factor binding sites a motif similarity score (MSS) of 80%
was applied.
4.10. Statistical analysis
A two-sided type I error rate of P¼0.05 was chosen for the
analyses. No correction for multiple testing was performed
with respect to the exploratory design and modest statistical
power of this study. Student’s t-tests were used as indicated
to evaluate the statistical significance of the normally dis-
tributed data sets of real time RT-PCR and ChIP analyses.
One-way ANOVA followed by Bonferroni’s multiple compar-
ison tests were used to examine the statistical significance of
the normally distributed luciferase assay results.
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Pernhorst et al., Supplemental Figure 1 
Luciferase reporter construct including different promoter variants of HTR1a at the 
rs6295 site. We inserted a 1102bp promoter fragment (black box) of the predicted 
promoter region upstream of the HTR1a gene to control a luciferase reporter gene. The 
short sequences above the fragments represent the different promoter variants (a bold 
C for the major and a bold G for the minor rs6295 variant).
00.04
0.08
0.12
0.16
0.20
CC GG CG
re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n
HTR1a
*
Pernhorst et al., Supplemental Figure 2 
The relative mRNA expression of HTR1a is significantly more abundant in the group of TLE patients 
homozygous for the rs6295 C-allele (n=23; 0.159 ± 0.03; black bar) compared to the group carrying the 
CG genotype (n=38; 0.065 ± 0.02; grey bar; one-way ANOVA with Bonferroni‘s multiple comparison 
tests: *p<0.05). Compared to the group of TLE patients homozygous for the rs6295 G-allele (n=20; 
0.074 ± 0.01; white bar), the group of TLE patients carrying the CC-genotype showed a significant 
increase in relative mRNA expression of HTR1a (n=20; 0.07 ± 0.01; white bar; one-way ANOVA with 
Bonferroni‘s multiple comparison tests: *p<0.05). HTR1a expression in patients with the rs6295 GG-
genotype differs not significantly compared to patients harbouring the rs6295 CG genotype. 
*
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Pernhorst et al., Supplemental Table 1:  
 
Summary of clinical patient parameters.  
Table describing the clinical parameters of the TLE patients group including the 
number of all TLE patients, the number of blood samples, the number of brain 
samples, the percentage of gender, the percentage of pathology, mean of age at 
seizure onset in years, mean of age at epilepsy surgery in years and mean of BDI. 
Absolute number of patients with available clinical data is indicated in brackets.  
Biopsy specimens were neuropathologically analyzed according to standard 
procedures and hippocampi stratified according to the pathlogical pattern of the 
patient into the two following groups: AHS (Ammon’s horn sclerosis) and lesion 
associated (ganglioglioma, cavernoma, dysembryoplastic neuroepithelial tumor). 
Notably, also hippocampi of patients with lesion associated TLE show substantial 
reactive astrogliosis in the hippocampal formation.  
 
Number of patients 181 
Number of blood samples 41 
Number of brain samples 140 
Gender (male / female) [181] 48.62 / 51.38 
Pathology (AHS / lesion associated) [160] 77.71 / 22.29 
Age of seizure onset [172] 12.45 ± 0.87 
Age at epilepsy surgery [159] 32.45 ± 1.16 
BDI [56] 32.45 ± 1.16 
 
 
Pernhorst et al., Supplemental Table 2 
A) Genotype and allele frequency of the rs6295 SNP in the TLE group and of rs6449693 in the control group. Both the genotype 
and allele frequencies in the TLE group according to rs6295 and the genotype and allele frequencies in the control group according to 
rs6449693 are presented. Relative as well as absolute (in italics) genotype and allele frequencies are given. Results of Χ²-test and two-
tailed P value are shown. The genotype distribution in the control was not significantly different from those expected by Hardy-Weinberg 
equilibrium. 
    Genotype frequency  Allele frequency 
              
SNP Gene Group n CC CG GG Χ² P  Allele C Allele G Χ² P 
rs6295 HTR1a TLE 140 0.25 (35) 0.49 (68) 0.26 (37) 0.27 0.875  0.49 (138) 0.51 (142) 0.036 0.85 
              
    AA AG GG    Allele A Allele G   
rs6449693 HTR1a Control* 2242 0.24 (550) 0.51 (1136) 0.25 (556)    0.5 (2236) 0.5 (2248)   
              
*Control according to HNR cohort 
 
 
 
B) Genotype and allele frequency of the rs6295 SNP in patients suffering from TLE “with depression” versus those “without 
depression” groups. Additional blood DNA was obtained from TLE patients with depression (n=56), who have not yet undergone 
epilepsy surgery. Data is presented parallel to A). However, we do not observe significant differences in the allele or genotype frequency 
distributions between both groups (Χ²-test and two-tailed P value). 
 
     Genotype frequency  Allele frequency 
               
SNP Gene Group Depression n CC  CG  GG Χ² P  Allele C  Allele G  Χ² P 
rs6295 HTR1a TLE + 70 0.3 (21) 0.471 (33) 0.229 (16) 0.79 0.67  0.536 (75) 0.464 (65) 0.836 0.36 
  TLE - 108  0.25 (27) 0.472 (51) 0.278 (30)    0.486 (105) 0.514 (111)   
Pernhorst et al., Supplemental Table 3: 
 
Genotype distributions of candidate SNP 
The genotype distributions of the candidate SNP stratified according to distinct 
clinical characteristics. Variables are expressed in absolute numbers (Χ²-test and 
two-tailed P value). Intriguingly, this co-variance analysis results in no significant 
correlation of individual clinical parameters with distinct genotypes of HTR1a. 
 
 
A) Clinical data of mTLE patient: correlation to HTR1a  genotypes. 
 
Genotype characteristics CC CG GG Χ² P 
 
     
Gender (Male / Female) 25/25 41/43 27/20 0.95 0.62 
 
     
Number of Seizures per month  
(0-10 / 11-20 / 21- more than 
100) 
34/6/6 64/7/10 33/3/10 3,24 0.52 
      
Age at seizure onset in years 
(1-10 / 11-50) 27/18 36/45 29/17 5.12 0.77 
 
     
Age at epilepsy surgery in 
years (1-10 / 11-64) 4/39 7/68 2/39 0.8 0.67 
      
Pathology  (AHS /  
Rasmussen’s encephalitis / 
lesion associated) 
35/0/11 56/1/14 31/0/10 1.62 0.91 
      
Drug therapy (sodium channel 
blocker monotherapy / 
levetiracetam combinations / 
non-levetiracetam 
combinations) 
11/14/20 18/34/27 12/17/15 2.23 0.69 
 
 
 
 
 
B) Clinical data of mTLE patients: correlation to gene expression of HTR1a. 
 
Clinical variables Mean SEM P 
  
 
 
Gender (Male / Female) 0.12 / 0.12 0.03 / 0.02 0.911 
 
   
Number of Seizures per month  
(0-10 / 11- more than 100) 0.11 / 0.13 0.02 / 0.04 0.618 
    
Age at seizure onset in years 
(1-10 / 11-50) 0.13 / 0.11 0.02 / 0.02 0.592 
 
   
Age at epilepsy surgery in 
years (1-10 / 11-64) 0.313/ 0.12 0.03 / 0.01 0.902 
    
Pathology  (AHS /  
Rasmussen’s encephalitis + 
lesion associated) 
0.12 / 0.13 0.02 / 0.03 0.859 
 
Pernhorst et al., Supplemental Table 4: 
 
Genotype distributions of candidate SNP with response to antipsychotic 
treatment. 
The genotype and allele distributions of the candidate SNP stratified with response to 
antipsychotic treatment. Variables are expressed in absolute numbers (Χ²-test and 
two-tailed P value).  
 
 
A) Association of the HTR1a promoter SNP rs6295 with response to 
antipsychotic treatment. 
 
 Genotype frequency  Allele frequency 
           
Group CC CG GG Χ² P  Allele C Allele G Χ² P 
           
antipsychotic 
treatment 0.17 (3) 0.53 (9) 0.29 (5) 0.92 0.63  0.44 (15) 0.56 (19) 0.62 0.43 
           
no antipsychotic 
treatment 0.29 (46) 0.45 (73) 0.26 (42)    0.51 (165) 0.49 (157)   
           
 
 
 
B) Association of the HTR1a promoter SNP rs6295 with response to 
antipsychotic treatment in depressive patients. 
 
 Genotype frequency  Allele frequency 
           
Group CC CG GG Χ² P  Allele C Allele G Χ² P 
           
antipsychotic treatment 0.2 (2) 0.6 (6) 0.2 (2) 1.11 0.57  0.14 (10) 0.15 (10) 0.08 0.78 
 
   
 
      
no antipsychotic treatment 0.32 (19) 0.42 (25) 0.25 (15)    0.86 (63) 0.85 (55)   
           
 
 
 
C) Association of the HTR1a promoter SNP rs6295 genotype with response to 
BDI level. 
Rs6295 genotype Mean of BDI SEM P 
    
CC / GG 14.93 / 16.47 2.18 / 2.01 0.607 
    
 
D) Correlation of the HTR1a gene expression to antiepileptic drug treatment 
using Bonferroni's Multiple Comparison Test. 
 Mean difference t P value 
Drug group 1 ( sodium-channel 
blockers monotherapy) vs. 
drug group 2 (LEV-
combinations) 
0.09172 0.08194 P > 0.05 
 
   
Drug group 1 ( sodium-channel 
blockers monotherapy vs. drug 
group 3 (non-LEV 
combinations) 
 
-1.354 1.347 P > 0.05 
 
   
Drug group 2 (LEV-
combinations) vs. drug group 
3 (non-LEV combinations) 
-1.446 1.354 P > 0.05 
 
 
 
E) Correlation of the c-Jun gene expression to antiepileptic drug treatment 
using Bonferroni's Multiple Comparison Test. 
 Mean difference t P value 
Drug group 1 ( sodium-channel 
blockers monotherapy) vs. 
drug group 2 (LEV-
combinations) 
480.3 1.69 P > 0.05 
 
   
Drug group 1 ( sodium-channel 
blockers monotherapy vs. drug 
group 3 (non-LEV 
combinations) 
 
230.1 1.112 P > 0.05 
 
   
Drug group 2 (LEV-
combinations) vs. drug group 
3 (non-LEV combinations) 
-250.3 0.9077 P > 0.05 
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4.3 Summary
Not only epilepsies but many neuropsychiatric disorders manifest with episodic onset
of symptoms. In respective disorders, large-scale genetic analyses have a characterized
variety of allelic variants, often SNPs, that are non-coding. Many of them are located
in putative gene promoter regions. These aspects hold particularly true for depres-
sion and migraine. For obvious reasons, brain tissue of respective patients is generally
not available. However, native human brain tissue would allow intriguing insights, i.e.
transcriptional analyses of corresponding genes in order to determine, whether distinct
SNPs have promoter relevant activity. Biopsy brain tissue samples of pharmacoresis-
tant temporal lobe epilepsy patients that undergo epilepsy surgery for seizure control
represent a unique option in order to overcome these obstacles and stratify patients
according to variants of the putative promoter SNPs for corresponding expression anal-
ysis of respective genes in human brain tissue.
By concentrating on a prominent SNP (rs6295) that has been associated with several
neuropsychiatric disorders including migraine, we here followed this approach. Analysis
of the SNP rs6295 and HTR1a expression in human TLE tissue occurred reasonable to
us also in an epileptological context. The serotonin signaling system has been claimed
to be relevant for focal epilepsies (Theodore et al., 2012). Furthermore rs6295 had been
described as functional binding site for transcriptional repressors (Lemonde et al., 2003;
Albert et al., 2011). Here, we have further explored, whether the respective promoter
motif may in addition be a binding site for activating transcription factors. This may
provide substantial more complex regulative potential of this prominent promoter site.
In the present study we demonstrated a putative binding site for the transcription
factor c-Jun at the position of the SNP rs6295 in the HTR1a promoter with allele-
specific binding affinity using bioinformatic approaches. The allele-variants of SNP
rs6295 affect the differential binding of c-Jun to the promoter region. As previously
predicted, the C variant of the SNP rs6295 results in higher promoter activity com-
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pared to the G variant after exposure with the activating TF c-Jun using in vitro
reporter assays. The relevance of the SNP rs6295 on HTR1a expression levels is given
by significant differences of mRNA expression in hippocampal tissue in patient groups
homozygous for C and G alleles, respectively. In contrast to previous findings which
demonstrate binding of transcriptional repressors NUDR and Hes5 to the SNP rs6295
C allele (Lemonde et al., 2003; Albert et al., 2011), we found an enhanced HTR1a ex-
pression in patients harboring the rs6295 genotype CC. In human hippocampal tissue
originating from epilepsy surgery, the analysis of mRNA expression levels reveals no
differences of transcriptional repressors NUDR and Hes5 in individuals homozygous
for the SNP rs6295 alleles. Furthermore, the increased HTR1a expression correlates to
the repressor-antagonizing effect of the activating factor c-Jun in patients homozygous
for C allele.
In summary, this study indicates c-Jun as immediate early gene to have a modulatory
effect on HTR1a expression. With respect to an increase in neuronal activity in surgi-
cal brain tissue of TLE patients under study, our data suggest a transient rise of c-Jun
expression. This leads to alterations in HTR1a expression, in particular for individu-
als harboring the C allele of the SNP rs6295. This mechanism may lead to impaired
serotonin homeostasis. A link between imbalanced serotonergic signaling system and
seizure generation has been suggested by multiple studies (Lesch, 2001; Trindade-Filho
et al., 2008). Knockout mice lacking 5HT1ARs manifest increased seizure activity, that
implicates serotonin receptors in the regulation of neuronal excitability (Sarnyai et al.,
2000).
However, susceptibility to seizures may also be increased by multiple other factors such
as inflammatory processes. For example, recent studies connect increased neuronal ex-
citability and epileptogenesis to inflammatory processes (Vezzani et al., 2013). Never-
theless, the influence of specific inflammatory factors on seizure frequency is still poorly
examined. In order to investigate the correlation of functional parameters dependent of
epilepsy including seizures, we analyzed it using the example of inflammatory mediators
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known to be implicated in seizure generation and epileptogenesis.
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5 TLR4, ATF-3 and IL8 inflammation mediator ex-
pression correlates with seizure frequency in hu-
man epileptic brain tissue
5.1 Introduction
Recent evidence supports the increased presence and activation of immune and inflam-
matory pathways as one major factor in epilepsy development (Aarli, 2000; Vezzani and
Granata, 2005). Inflammatory responses can be triggered by transient brain damaging
events such as neurotrauma, infection, febrile seizures or status epilepticus (Pitkanen
and Sutula, 2002; Dinarello, 2004; Bartfai et al., 2007). A contribution to seizure de-
velopment and maintenance, cell loss and permeability as well as neuronal network
hyperexcitability has been claimed in animal models (Friedman et al., 2009; Vezzani
et al., 2011; Dedeurwaerdere et al., 2012). Previous immunohistochemical studies sug-
gest a potential release of inflammatory mediators by glia, neurons, endothelial cells of
the blood-brain-barrier as well as peripheral immune cells into the brain parenchyma
under lesion conditions (Ransohoff et al., 2003; Banks and Erickson, 2010).
Toll-like receptors (TLRs) play a prominent role in the innate immune system in in-
ducing inflammatory processes by enhancing cytokine transcription (Maroso et al.,
2010). A major TLR family member, the human Toll-like receptor 4 (TLR4) was first
identified in mammalians (Medzhitov et al., 1997) and is mainly expressed in brain
(Chakravarty and Herkenham, 2005). In animal studies, TLR4 protein is expressed
1h and 3h after seizure onset in neurons within the pyramidal layer and glial fibrillary
acidic protein (GFAP)-positive astrocytes (Maroso et al., 2010). In TLE patients with
hippocampal sclerosis TLR4 was found in pyramidal neurons and GFAP-positive as-
trocytes (Maroso et al., 2010).
TLR-signaling is the main element of innate immune defence. The adaptive response
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gene Activating transcription factor 3 (ATF-3) represents a key regulator of innate
immune responses (Thompson et al., 2009). In recent years, ATF-3 has received par-
ticular attention for being activated by stressful stimuli (Thompson et al., 2009). It
interacts with inflammation-related genes, e.g. through down-regulation of TLR4 or
regulation of several cytokines such as interleukin 1 beta, interleukin 6, interleukin
12, tumor necrosis factor alpha and chemokine (C-C motif) ligand 4 (Gilchrist et al.,
2006). ATF-3 is upregulated in nuclei of dentate gyrus neurons after injection of the
neuroexcitatory stimulant kainate (Francis et al., 2004). In contrast, there is a low
ATF-3 expression in intact neurons such as facial motor neurons of mice (Parsadanian
et al., 2006).
Cytokines represent key immunological and inflammatory mediators. Interleukin 8
(IL8), also known as CXC Motif Chemokine 8 (CXCL8), is an essential mediator be-
longing to the Cysteine X Cysteine (CXC) chemokine family (Vlahopoulos et al., 1999).
Significantly abundant levels of IL8 are present in patients with severe traumatic brain
injuries (Kushi et al., 2003). Another study indicates a correlation of increased levels
of IL8 with dysfunction of the blood-brain barrier (Kossmann et al., 1997).
The impact of seizure frequency and additional clinical parameters on gene expression
of inflammatory mediators such as TLR4, ATF-3 and IL8 is largely unknown in human
TLE. We here investigate these aspects on the basis of human surgical brain tissue in
the subsequent manuscript.
The following manuscript published in May 2013 in Seizure is allowed by Elsevier
Journals to be include in a thesis or dissertation with full acknowledgment of the final
article.
My contribution to this work includes besides the sample preparation, the main im-
munohistochemical experiments for assessment of TLR4, ATF-3 and IL8 protein local-
ization in human hippocampal brain tissue and the correlation analyses between gene
expression levels of inflammatory mediators and seizure frequency. Additionally, I have
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performed the statistical data evaluation and wrote the manuscript.
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TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure
frequency in human epileptic brain tissue
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1. Introduction
Brain injuries such as neurotrauma, febrile seizures, infections
or status epilepticus induce inflammatory responses and this in
turn can be associated with acute symptomatic seizures and a high
risk of developing chronic epilepsy.1,2 In human patients only little is
known about differential expression of inflammatory factors in
correlation to seizure frequency and other clinical parameters. In
this context, we have focused on the key human inflammatory
mediators, toll-like receptor 4 (TLR4), ATF-3 and IL8, for the following
reasons: TLR4 has previously been shown as key trigger of
inflammation by inducing the gene transcription of several
cytokines and contribute to seizure formation and severity in a
TLE animal model.3 In kainate-induced epileptic mice and in
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Purpose: Data from animal models has nicely shown that inflammatory processes in the central nervous
system (CNS) can modulate seizure frequency. However, a potential relationship between the
modulation of seizure frequency and gene expression of key inflammatory factors in human epileptic
tissue is still unresolved. Brain tissue from pharmacoresistant patients with mesial temporal lobe
epilepsy (mTLE) provides a unique prerequisite for clinico-neuropathological correlations. Here, we have
concentrated on gene expression of the human key inflammatory mediators, TLR4, ATF-3 and IL8, in
correlation to seizure frequency and additional clinical parameters in human epileptic brain tissue of
pharmacoresistant mTLE patients. Furthermore, we characterized the cell types expressing the
respective proteins in epileptic hippocampi.
Methods: Total RNAs were isolated from n = 26 hippocampi of pharmacoresistant mTLE patients using
AllPrep DNA/RNA Mini Kit. cRNA was used for hybridization on Human HT-12 v3 Expression BeadChips
with Illumina Direct Hybridization Assay Kit and resulting gene expression data was normalized based
on the Illumina BeadStudio software suite by means of quantile normalization with background
subtraction. Corresponding human hippocampal sections for immunohistochemistry were probed with
antibodies against TLR4, ATF-3, IL8 and glial fibrillary acidic protein (GFAP), neuronal nuclear protein
(NeuN) and the microglial marker HLA-DR.
Results: We observed abundant TLR4 gene expression to relate to seizure frequency per month. For ATF-
3, we found an inverse correlation of expression to seizure frequency. Lower expression of IL8 was
significantly associated with high seizure frequency. Further, we detected TLR4 expression in neurons
and GFAP-positive astrocytes of pharmacoresistant mTLE patients. Only neurons of human epileptic
hippocampi express ATF-3. IL8 was expressed in microglia and reactive astrocytes.
Conclusion: Our results suggest a differential correlation of key inflammatory factor expression in
epileptic hippocampi and seizure frequency in patients. The modulation of such processes may open new
therapeutic perspectives for treating seizures.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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hippocampi of pharmacoresistant TLE patients, TLR4 was expressed
in pyramidal neurons and GFAP-positive astrocytes.3 A negative
regulator of TLR4,4 the immediate early and adaptive response gene
ATF-3 modulates the expression of genes critically involved in
inflammatory responses.5 ATF-3 expression is dynamically altered
by the exposure of cells to many stimuli including epileptic activity
in the brain.6 IL8, as one of the first chemokines identified in the
human brain, is known to be expressed exclusively in humans but
not in rodents. Previous data suggest expression of IL8 particularly in
microglia and astrocytes7 and an association of intrathecal IL8
synthesis and seizure frequency has been reported.8 Furthermore,
ATF-3 impacts the expression of chemokines.9 Here, we have used
our unique access to human epileptic brain tissue from epilepsy
surgery in order to investigate the role of these key mediators of
inflammatory processes in correlation to seizure frequency.
2. Materials and methods
We used human bioptic brain tissue to analyze the gene
expression data in correlation to the seizure frequency from
patients (n = 26) with chronic pharmacoresistant mTLE,10 who
underwent surgical treatment in the Epilepsy Surgery Program at
the University of Bonn Medical Center. The patient group under
study (n = 26 Caucasians) is particularly well characterized with
respect to seizure documentation and represents substantial
differences in seizure frequency (Supplemental Table 1). In all
patients, presurgical evaluation using a combination of non-
invasive and invasive procedures revealed that seizures originated
in the mesial temporal lobe.11 Surgical resection of the hippocam-
pus was clinically indicated due to pharmacoresistance in every
case and all procedures were conducted in accordance with the
Declaration of Helsinki and approved by the ethics committee of
the University of Bonn Medical Center. Informed written consent
was obtained from all patients. Based on screening the Center’s
fresh frozen hippocampal tissue bank by fresh frozen sections and
hematoxylin & eosin staining, care was taken to provide tissue
samples representing all hippocampal subfields from the corpus
hippocampi for every case included in the present study. Whereas
the majority of hippocampi revealed the pattern of Ammon’s horn
sclerosis (AHS; segmental neuronal cell loss and concomitant
astrogliosis and microglia activation), the other hippocampi in the
present series lacked the characteristic segmental neuronal cell
loss but showed astrogliosis and microglia activation. Those were
associated with lesions such as cortical dysplasia or epilepsy-
associated tumors. Diagnosis according to international criteria
was established by an experienced neuropathologist (AJB) in every
case.12,13 In the course of establishing a nucleic acid bank of
respective specimens, genomic DNA and total RNA were isolated
from hippocampal tissue samples using AllPrep DNA/RNA Mini Kit
(Qiagen, Hilden) according to manufacturer’s protocol. For the
following analyses, we used only the respective RNA. A total
amount of 750 ng cRNA was used for hybridization on Human HT-
12 v3 Expression BeadChips with Illumina Direct Hybridization
Assay Kit (Illumina, San Diego, CA). The data we extracted for genes
of interest was previously analyzed using Illumina’s GenomeStu-
dio Gene Expression Module. Gene expression data were normal-
ized using the Illumina BeadStudio software suite by means of
quantile normalization with background subtraction. Expression
values that were ‘‘not detectable’’ for individual genes, were
omitted from the further analysis. Human hippocampal paraffin
slices were stained with antibodies against TLR4 (1:20; Santa Cruz
Biotechnology, Heidelberg; sc-10741), ATF-3 (1:500; Santa Cruz
Biotechnology, Heidelberg; sc-22798), IL8 (1:200; Santa Cruz
Biotechnology, Heidelberg; sc-7922) and Glial fibrillary acidic
Protein (GFAP) (1:350; Sigma–Aldrich, Munich, Germany; G3893),
neuronal nuclear protein (NeuN) (1:500; Millipore, Billerica, MA
USA; MAB377) and HLA-DR (1:1000; Dako, Hamburg, Germany;
M0746). Correlation analyses between gene expression levels in
Fig. 1. Relative gene expression of TLR4, ATF-3 and IL8 in correlation to seizure frequency. (A) Abundant TLR4 expression significantly correlated with high seizure frequency in
patients with pharmacoresistant mTLE (r = 0.408; *p = 0.02; n = 24). (B) Low ATF-3 expression levels are significantly associated with high seizure frequency in mTLE patients
(r = 0.431; *p = 0.01; n = 26). (C) Relative expression data revealed a significant correlation of low IL8 expression and high seizure frequency (r = 0.675; ***p = 1.7  1004;
n = 23). Different n-numbers for the individual genes are due to the fact that expression values that were ‘‘not detectable’’ had to be omitted from the analysis.
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whole hippocampus and variable seizure frequency were done by
the Pearson product moment correlation (r) and the correlation t-
test (p) using the statistical language R.
3. Results and discussion
We investigated the expression and distribution of the key
inflammatory mediators TLR4, ATF-3 and IL8 in human hippocam-
pal tissue and a potential correlation of seizure frequency and
expression of respective genes. We observed that abundant TLR4
expression correlated significantly with high seizure frequency
(Pearson correlation coefficient: r = 0.407; two-tailed t-test:
p = 0.047; n = 24; Fig. 1A). For ATF-3 we found that patients with
high seizure frequency show low levels of gene expression
(r = 0.431; two-tailed t-test: p = 0.027; n = 26; Fig. 1B). The
minor ATF-3 expression and abundant TLR4 expression in patients
with high seizure frequency may support the role of ATF-3 as a
negative regulator of TLR4 signaling in human epileptic hippo-
campi.4 Furthermore, ATF-3 has been suggested as a regulator of
chemokine expression.9 Low expression of the human specific IL8
chemokine is significantly correlated with high seizure frequency
(r = 0.671; two-tailed t-test: p = 1.7  1004; n = 23; Fig. 1C).
Intriguingly, in our present analyses the human-specific
inflammatory mediator IL8 showed the most significant correla-
tion of gene expression and seizure frequency in human epileptic
brain tissue. Particularly, these data may underline the need for
analyses in human epileptic tissue complementary to animal
models, where these analyses for obvious reasons are not possible.
In order to address co-correlation of the reported associations of
gene expression levels with other clinical parameters, we carried
out a comprehensive co-variance analysis of clinical and thera-
peutic data of the patients included here (Supplemental Table 2).
These analyses did not result in significant associations of TLR4,
ATF-3 and IL8 mRNA expression with any of the additional
individual parameters investigated. Complementarily, we exam-
ined potential inter-correlations among the three inflammatory
mediator expression levels based on the seizure frequency. To this
end, we performed a one-way MANOVA to test for comprehensive
expression dynamics of the inflammatory mediators under study.
One-way MANOVA revealed a significant multivariate main effect
in the expression of inflammatory mediators based on seizure
frequency (Pillai’s trace statistic = 2.281, F(45, 27) = 1.905,
p = 0.039). Power to detect the effect was 0.943 (Supplemental
Table 3).
Recent studies in hippocampal tissue of pharmacoresistant
mTLE patients with hippocampal sclerosis indicated TLR4
Fig. 2. Immunohistochemical analyses of TLR4, ATF-3 and IL8 in human hippocampal tissue. (A1) Co-immunoreactions against NeuN and GFAP (both green, as indicated)
antibody showed that TLR4 (red) is localized in neurons and reactive astrocytes in mTLE patients (scale bar = 100 mm). (A2) In higher magnification, TLR4 (red signal) is
expressed in both, neurons and reactive astrocytes (scale bar = 50 mm). (B1) ATF-3 (red) is localized in neurons (NeuN, green; scale bar = 100 mm) in mTLE patients. (B2) ATF-
3 (red) is strongly expressed in representative neurons (scale bar = 50 mm). (C1) Co-immunohistochemistry against the microglial protein HLA-DR (green) and the astrocytic
protein GFAP (green) showed that IL8 (red) is expressed in microglia and reactive astrocytes (scale bar = 100 mm). (C2) Higher magnification confirms the presence of IL8 (red)
in microglia and reactive astrocytes (scale bar = 50 mm). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
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expression in pyramidal neurons and GFAP-positive astrocytes.3
We found consistent expression patterns in pharmacoresistant
mTLE patients by immunohistochemical reactions with antibodies
against GFAP and NeuN (Fig. 2A). We did not observe TLR4
expression in microglia (data not shown). The presence of TLR4 in
neurons and reactive astrocytes in human epileptic tissue and the
increased expression in patients with high seizure frequency may
underline a potential modifying role of TLR4 for seizure frequency
in human epilepsy. Previous data suggested expression of ATF-3 in
nuclei of dentate gyrus granule cells after kainate induced
epilepsy.14 Glial cells as well as reactive astrocytes lacked ATF-3
expression.15 By double immunofluorescence, we here observed
ATF-3 expression in neurons expressing NeuN in paraffin sections
of human hippocampal tissue (NeuN, Fig. 2B). Expression of ATF-3
protein was neither detected in glial components such as reactive
astrocytes (data not shown) nor in microglia components (data not
shown). In contrast, the chemokine IL8 has been described to be
produced exclusively by microglial cells and astrocytes.7 We
performed double-immunofluorescence analyses using antibodies
directed against HLA-DR and GFAP to investigate the expression of
IL8 in human hippocampal brain tissue. We found IL8 as expressed
in both, microglia and reactive astrocytes (Fig. 2C). However, IL8
revealed no co-expression with the neuronal marker NeuN (data
not shown).
Our results suggest a substantial correlation between gene
expression of inflammatory key mediators and seizure frequency
in epileptic patients. Considering the fact that factors under study
are differentially expressed in pharmacoresistant mTLE hippo-
campi, pharmacological interference with such cascades may
provide new vistas of anticonvulsive therapy in the future.
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Pernhorst et al., Supplemental Table 1: 
Summary of patient parameters. 
(A)  Parameters  including  gender,  post-operative  outcome,  pathology  and  drug 
therapy  are  presented  in  percentage  values.  The  absolute  number  of  available 
clinical data is indicated in brackets. Age at epilepsy surgery in years, age at seizure 
onset in years, seizure frequency per month are presented in mean ± SEM values. 
Information on number of seizures per month relies partially on patients’ information 
and is therefore variable. The post-operative outcome is classified according Engel 
classification (class I A: completely seizure free; class IV B: no seizure reduction). 
Biopsy  specimens  were  neuropathologically  analyzed  according  to  standard 
procedures and hippocampi  stratified according to  the pathological  pattern of  the 
patient  into  the  two  following  groups:  AHS (Ammon’s  horn  sclerosis)  and  lesion 
associated  (ganglioglioma,  cavernoma,  dysembryoplastic  neuroepithelial  tumor). 
Notably,  also hippocampi of patients with  lesion associated TLE show substantial 
reactive astrogliosis in the hippocampal formation. 
A) Distribution of clinical parameters within sample group.
Number of patients 26
Gender (male vs. female) [26] 57.69% vs. 42.31%
Age at seizure onset in years [22] 15.9 ± 2.5
Seizure frequency per month [26] 39.25 ± 9.74
Drug therapy (Sodium-channel blockers monotherapy vs. LEV-
combinations vs. non LEV-combinations) [25]
28% vs. 36% vs. 36%
Age at epilepsy surgery in years [26] 33.73 ± 3.42
Post-operative outcome (Engel IA vs. Engel IV B) [24] 62.5% vs. 37.5%
Pathology (AHS vs. lesion associated) [26] 57.69% vs. 42.31%
Pernhorst et al., Supplemental Table 2
The gene expression of the inflammatory key mediators TLR4, ATF-3 and IL8 in 
correlation to clinical parameters.
The  co-variance analyses of expression of  TLR4, ATF-3  and IL8  did not result in 
significant correlation with individual clinical parameters. Variables are presented in 
mean ± SEM values. 
A) Clinical data of TLE patients: correlation to gene expression of TLR4
Clinical variables Mean SEM P
Gender (Male / Female) 17.65 / 16 2.41 / 3.94 0.72
Age at seizure onset in years (1-10 / 11-50) 18.69 / 15.97 4.1 / 3.42 0.639
Age at epilepsy surgery in years (1-10 / 11 and more) 11.22 / 17.31 0.75 / 2.62 0.41
Seizure-free post-operative (I A / IV B) 15.03 / 19.09 3.28 / 2.78 0.422
Pathology  (AHS / lesion associated) 18.9 / 14.29 3.08 / 2.79 0.315
B) Clinical data of TLE patients: correlation to gene expression of ATF-3
Clinical variables Mean SEM P
Gender (Male / Female) 56.97 / 37.29 11.35 / 4.21 0.181
Age at seizure onset in years (1-10 / 11-50) 34.49 / 57.84 5.81 / 9.95 0.116
Age at epilepsy surgery in years (1-10 / 11 and more) 22.48 / 49.43 7.22 / 6.89 0.175
Seizure-free post-operative (I A / IV B) 40.07 / 56.05 3.95 / 15.05 0.242
Pathology  (AHS / lesion associated) 47.15 / 50.67 7.46 / 13.18 0.858
C) Clinical data of TLE patients: correlation to gene expression of IL8
Clinical variables Mean SEM P
Gender (Male / Female) 48.19 / 40.25 8.74 / 7.03 0.589
Age at seizure onset in years (1-10 / 11-50) 37.51 / 56 14.59 / 5.66 0.219
Age at epilepsy surgery in years (1-10 / 11 and more) 13.13 / 47.61 8.28 / 6.8 0.084
Seizure-free post-operative (I A / IV B) 41.02 / 45.99 6.55 / 11.76 0.717
Pathology  (AHS / lesion associated) 50.45 / 36.88 7.93 / 10.56 0.338
D) Correlation of the TLR4 gene expression to antiepileptic drug treatment 
using Bonferroni’s Multiple Comparison Test.
Mean difference t P value
Sodium-channel blockers mono-
therapy vs. LEV-combinations 1.931 0.2823 P > 0.05
sodium-channel blockers mono-
therapy vs. non-LEV combina-
tions 5.968 0.8516 P > 0.05
LEV-combinations vs. non-LEV 
combinations 4.037 0.6403 P > 0.05
E) Correlation of the ATF-3 gene expression to antiepileptic drug treatment 
using Bonferroni’s Multiple Comparison Test.
Mean difference t P value
Sodium-channel blockers mono-
therapy vs. LEV-combinations -13.13 0.8031 P > 0.05
Sodium-channel blockers mono-
therapy vs. non-LEV combina-
tions 17.57 1.049 P > 0.05
LEV-combinations vs. non-LEV 
combinations 30.70 2.037 P > 0.05
F) Correlation of the IL8 gene expression to antiepileptic drug treatment using 
Bonferroni’s Multiple Comparison Test.
Mean difference t P value
Sodium-channel blockers mono-
therapy vs. LEV-combinations -1.387 0.07012 P > 0.05
Sodium-channel blockers mono-
therapy vs. non-LEV combina-
tions -4.431 0.2692 P > 0.05
LEV-combinations vs. non-LEV 
combinations -3.044 0.1602 P > 0.05
Pernhorst et al., Supplemental Table 3
One-way MANOVA statistics comparing expression level of inflammatory 
mediators and seizure frequency. Parameters including the value of the Pillai’s 
trace test (Value), the overall F  statistic over all three dependent expression 
variables (F), the number of degrees of freedom in the model (Hypothesis df), the 
number of degrees of freedom associated with the model errors (Error df), the 
significance of the F statistic given as P value (Significance P value) and the 
statistical power to detect the effect (Observed Power).
Effect Statistic Value F Hypothesis df
Error 
df
Significance P 
value
Observed 
Power
Seizure 
frequency
Pillai’s 
Trace 2.281 1.905 45 27 0.039 0.943
5. Pernhorst et al., Seizure, 2013
5.3 Summary
In our study, we investigated the role of inflammatory mediator gene expression levels
in the context of seizure propensity and other clinical aspects of epilepsy. We observed
a differential correlation of mRNA expression levels of inflammatory mediators includ-
ing TLR4, ATF-3 and IL8 and seizure frequency in human surgical brain tissue of
TLE patients. In order to correlate gene expression levels and seizure frequency of
TLE patients, we stratified between low and high seizure frequency. Here, we defined
low seizure frequency as a range of 0 to 10 seizures per month, whereas high seizure
frequency is given by 30 to more than 100 seizures per month.
Our study reveals a significant impact of seizure frequency on TLR4 expression. TLR4
expression is significantly increased in a group of TLE patients characterized by high
seizure frequency compared to patients with low seizure frequency. Our data indicates
TLR4 protein expression in neuronal as well as astrocytic components of hippocampal
brain tissue, confirming previous data (Maroso et al., 2010). Interestingly, the increased
TLR4 expression in patients with high seizure frequency may suggest this molecule as
target for modulating seizure frequency in human epilepsy. As shown by Maroso et al.,
an epileptogenic insult may stimulate TLR4 activation which is then sustained by the
recurrence of epileptic activity (Maroso et al., 2010).
Interestingly, ATF-3 as a negative regulator of TLR4 shows a significantly less abun-
dant gene expression in patients with high seizure frequency. In immunohistochemical
labelings, we detected ATF-3 protein expression in neurons of human epileptic hip-
pocampi but neither in glial nor microglia components in accordance with a recent
report (Ohba et al., 2003). ATF-3 is an immune regulator that functions in a context-
dependent manner, particularly by negative modulation of the TLR-signaling pathway
(Gilchrist et al., 2006) or by positive regulation of various cytokine and chemokines
of the interleukin family, Tumor necrosis factor alpha (TNFα) and Chemokine (C-C
motif) ligand 2 (CCL2) (Zmuda et al., 2010).
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A rodent homologue of human chemokine IL8 has not been identified to date and so
it is denoted as human-specific. Intriguingly, IL8 displays the strongest correlation of
gene expression and seizure frequency. We found that low expression of the human
specific IL8 is significantly correlated with high seizure frequency. This result may
demonstrate the relevance of analyzing molecular pathomechanisms in human surgical
brain tissue complementary to animal models. Immunohistochemical labelings with
antibodies directed against the microglia marker HLA-DR as well as the astrocytic
marker GFAP indicate both IL8 protein expression in microglia components and in re-
active astrocytes. The release of IL8 from microglia and reactive astrocytes in response
to infection or injury is established (Liu and Hong, 2003; Farina et al., 2007).
In conclusion, we demonstrate a significant correlation of expression of distinct medi-
ator genes of inflammation to seizure frequency in human epileptic brain tissue. With
respect to differential expression of inflammatory factors in human hippocampal tissue
of TLE patients, our results highlight the possibility to interfere with inflammatory
signaling pathways as potential new targets for therapeutic intervention, particularly
for epileptic patients not responding to antiepileptic drugs.
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6 Discussion
Epileptic seizures occur in a variety of different disorders. In generalized epilepsies
’mutational channelopathies’ have been frequently described (Weiergra¨ber et al., 2008;
Nabbout and Scheffer, 2013). These forms of epileptic disorders are generally rare. In
more frequent focal epilepsies, changes on mRNA level of genes including ion channels
(’transcriptional channelopathies’) and neurotransmitter receptors have been described,
whereas mutations of respective genes are rare (Oliveira et al., 2011). Focal epilepsies
represent multifactorial disorders. So, pathogenetic factors, episodically shifting the
brain over a virtual threshold to the emergence of seizures, are individually neither
necessary nor sufficient.
In recent years, several SNPs located in putative promoter regions have been claimed as
accumulated in episodic CNS disorders. Transiently altered expression of correspond-
ing genes therefore constitutes a potential pathogenetic aspect for the manifestation of
episodic symptoms. The availability of biopsy tissue from epilepsy surgery of pharma-
coresistant TLE patients provides a unique prerequisite in order to study the potential
impact of gene promoter variants on transcription as well as the abundance of molecules
involved in neurotransmission and immune responses in concert with stratification of
patients according to clinical parameters. Based on these considerations, we have ex-
plored several key pathogenetic aspects of epilepsy in respective human tissue samples.
On the molecular level, aberrant amounts of both excitatory, e.g. glutamate, and in-
hibitory, e.g. GABA, neurotransmitters have been observed in epilepsies. McNamara
et al. suggested that seizures are caused by a fundamental imbalance between excita-
tion and inhibition (McNamara, 1994).
Increasing evidence also suggests a role of serotonin in seizure development (Bagdy
et al., 2007). Altered concentrations of 5-HT receptors may directly or indirectly re-
sult in neuronal dysfunction (Barnes and Sharp, 1999). Likewise, Cavalheiro et al.
indicate an increased synthesis and utilization rate of hippocampal serotonin during a
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first SE (Cavalheiro et al., 1994). In humans with complex partial seizures, exposure
of fluoxetine, a serotonin reuptake inhibitor, leads to a decrease in seizure frequency
(Favale et al., 1995).
In order to study the contribution of genetic variability to transcriptional dynamics
in epilepsy, we examined allelic promoter variants in human biopsy brain tissue of
pharmacoresistant TLE patients. Due to the complexity of neuropathological changes
in TLE hippocampi, the involvement of multiple genes and signaling cascades in the
pathogenesis of TLE appears obvious. Numerous associations of genetic variations, in
particular SNPs, have been linked to brain dysfunction in general before (Urak et al.,
2006; Lorenz et al., 2006; Marziniak et al., 2007). Since such alterations have been
prominently shown in genes related to GABA-homeostasis and serotonergic transmis-
sion, we have concentrated in two studies of this thesis on respective pathways.
6.1 Distribution of allelic variants in distinct patient cohorts
Case-control studies represent one of the most common study designs in order to test
for disease associated allelic variants. Divergent allelic or genotypic distribution be-
tween either diseased individuals or healthy controls highlights potential risk variants.
Here, we initially genotyped DNA of pharmacoresistant patients suffering from TLE
to detect respective SNPs associated with brain disorders such as epilepsy, depression
and migraine, the latter also being potential comorbidities of focal epilepsies.
Our data revealed a significantly abundant C allele in the ALDH5A1 promoter SNP
rs1883415 when comparing the TLE-case group to a control group. Given the substan-
tial prevalence rate of neuropsychiatric disorders concomitting epilepsies, particularly in
case of major depressive episodes accompanying TLE (Swinkels et al., 2005; Kondziella
et al., 2007; Kanner, 2008), we further analyzed in the TLE patient cohort the existence
of depressive symptoms. In default of a large number of brain samples of TLE patients
with depressive symptoms, we extended the TLE patient population under study with
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blood DNA samples from additional TLE patients with depression. The frequency of
the SNP rs1883415 C allele in TLE patients with depression is significantly increased
compared to TLE patients lacking depressive symptoms.
In contrast, for GABRB3 promoter A/G variation rs4906902, we observe no significant
association for both alleles comparing TLE patient group and controls. Previously re-
ported associations indicated that the G allele as well as the A allele of SNP rs4906902
are differentially represented in patients with neurological disorders. For example, the
G allele is overrepresented in CAE (Urak et al., 2006), but could not be found in re-
mitting CAE patients when compared with healthy controls (Tanaka et al., 2012a).
With respect to the potential comorbidity of neuropsychiatric disorders to epilepsy,
we demonstrated that the G allele is more frequent in TLE patients with depression
as compared to patients showing no depressive symptoms. However, Feusner et al.
reported an association of the A allele to depression in patients with post-traumatic
stress disorder (Feusner et al., 2001). Given that depressive symptoms occur in different
pathologic contexts, alleles of GABRB3 promoter SNP rs4906902 may be differentially
overrepresented in depressive patients in a context dependent manner.
As previously shown, SNP rs6295 is associated with mood disorders including major
depression and bipolar disorder (Kishi et al., 2009, 2011). In fact, we neither detected
significant associations of particular SNP rs6295 allele nor genotype in TLE patients
versus non-epileptic controls (Schmermund et al., 2002). Likewise, we determined no
significant SNP rs6295 genotype as well as allele assocation in TLE patients with de-
pression compared to TLE patients without depression.
The allelic variants in the HTR1A promoter did in contrast not correlate to clinical pa-
rameters in TLE patients. In a following step, we correlated the presence of promoter
polymorphisms to gene expression.
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6.2 Impact of promoter SNPs on gene expression in episodic
brain diseases
About 30% of TLE patients are pharmacoresistant. Those TLE patients usually un-
dergo surgical therapy for effective seizure control (Engel, 1996b; Regesta and Tan-
ganelli, 1999).
Direct analysis of expression levels in diseased human surgical brain tissue specimens
provides a useful means to study allele-specific alterations in episodic brain diseases.
Thereby, we found that ALDH5A1 gene expression in TLE patients homozygous for
the A allele in the SNP rs1883415 to be significantly less abundant compared to TLE
patients homozygous for the C allele. Allele-specific expression of ALDH5A1 in TLE
patients stratified for the SNP rs1883415 genotype may relate to differential expression
of the enzyme SSADH. Reduced expression of SSADH and therefore lower turnover of
GABA, is at least partially comparable to SSADH deficiency which is associated with
clinical features such as generalized tonic-clonic and atypical absence seizures (Pearl
et al., 2003). With respect to an established relationship of disturbed GABA home-
ostasis with epileptogenic effects (Wong et al., 2003), our results reflect an interesting
aspect in neurotransmission of epileptic brain.
For GABRB3 and the SNP rs4906902, TLE patients with the GG genotype exhibit
a significantly decreased GABRB3 mRNA expression compared to TLE patients with
the AA genotype. This allele-dependent regulation of GABRB3 expression may reflect
an immediate effect on neurotransmission. As previously reported, reduced levels of
GABRB3 are accompanied by decreased levels of inhibitory GABAA receptors and
therefore may relate to an increase of seizure susceptibility (Tanaka et al., 2012b).
With respect to allele-specific expression differences of ALDH5A1 and GABRB3, it has
to be considered, that such differences may only manifest in situations of challenged
neuronal network conditions. Episodes such as febrile states or encephalitis per se
represent potentially hyperexcitable states with particular critical needs for inhibitory
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transmitter systems. Impaired turnover and also only slightly altered signaling of a
main inhibitory neurotransmitter system may under such conditions manifest as fail-
ure of network inhibition and contribute to the emergence of epileptic seizures. In this
context, our present observations may well contribute as explanation of the episodic
nature of epileptic symptoms.
Alterations in the serotonergic pathway can also contribute to the emergence of epilepsy.
Didelot et al. reported impaired 5-HT receptor binding in mesial temporal structures
of patients suffering from TLE (Didelot et al., 2008). As shown in section 4, we de-
tected allele-specific expression of HTR1a, a gene that encodes for a G protein-coupled
serotonin receptor. In the present study, individuals with the SNP rs6295 CC genotype
have more abundant HTR1a mRNA expression compared to patients homozygous for
the SNP rs6295 G allele. Irregular HTR1a expression levels lead to dysregulation of
5-HT release and therefore to an impaired serotonin homeostasis. Numerous studies
also suggest that disturbances in the serotonergic system are related to neuropsychi-
atric disorders including epilepsy, aggression, depression, anxiety and schizophrenia
(Savic et al., 2004; Siever, 2008; Filip and Bader, 2009). However the isolated notion
of a correlation of allelic variants in gene promoters and corresponding gene expression
in human brain tissue would be rather incomplete. Expressed transcription factors
potentially binding at promoter motifs should be taken into consideration. This step
of complexity we also aimed at in the studies of this thesis. These experiments had
implications as follows.
6.3 Allele-specific transcriptional regulation
Prior research emphasizes the impact of SNPs found in regulatory gene regions on tran-
scriptional modulation by either gene splicing, messenger RNA degradation, changes
in transcription factor binding or promoter activity (Lohrer and Tangen, 2000). There-
fore, we examined potential binding sites of transcription factors in given proximity of
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respective SNP positions. Subsequently, we investigated TF binding affinity in depen-
dence on the SNP. Bioinformatic predictions of potential TFBSs using position-specific
scoring matrices suggest differential allele-dependent binding affinity of regulatory TFs.
Concerning the SNP rs1883415 in the ALDH5A1 promoter, we identified a potential
TFBS for Egr-3. Egr-3 revealed significantly higher binding affinity to the C allele as
compared to the A allele. This result coincides with the substantially stronger C allele
promoter activation after exposure of the TF Egr-3 using luciferase reporter assays in
section 3. Honkaniemi et al. examined an increased Egr-3 mRNA expression level in a
rat TLE model after exposure to kainic acid to induce status epilepticus (Honkaniemi
and Sharp, 1999). Our data would be in line with an enhanced stimulation by Egr-3 on
ALDH5A1 expression level in patients particular homozygous for the C allele. Exper-
imental evidence also suggests that Egr-3 regulates expression of the α4 subunit of the
GABAA receptor in primary hippocampal neurons and in TLE models (Brooks-Kayal
et al., 1998; Roberts et al., 2005). Certain TFs may, therefore, orchestrate several
neurotransmitter systems in epileptogenesis in a highly complex fashion and manifest
overadditive effects.
Furthermore, stimulation of GABRB3 activity by the TF MEF-2 demonstrated signifi-
cantly increased promoter activity for the A allele in contrast to the G allele promoter.
This is in line with our previous prediction of a MEF-2 binding motif at the SNP
rs4906902. The predicted MEF-2 motif exhibits a more relevant sequence complemen-
tarity to the A allele promoter variant in comparison to the G allele variant. MEF-2
is highly expressed in brain. MEF-2 can be induced by extracellular stimuli, leading
to activation of a gene expression program to modulate an excitatory synapse activa-
tion on hippocampal neurons (Flavell et al., 2006). Additionally, MEF-2 was shown
as reduced in hippocampal tissue of pilocarpine-treated SE-rats at the chronic stage
compared to control rats (own unpublished data). In the light of these data, an atten-
uated activation of GABRB3 promoter may be the consequence in TLE.
With regard to the HTR1a promoter, we found that the SNP rs6295 is present in a
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potential binding region of transcriptional repressors as well as an activator. Former
studies reveal repressing effects on HTR1a by TFs NUDR and Hes5 (Lemonde et al.,
2003; Albert et al., 2011). Intriguingly, our data demonstrates a potential TFBS for
activating TF c-Jun. c-Jun has a higher binding affinity to the SNP rs6295 C variant
compared to G variant in the HTR1a promoter. Furthermore, this result is supported
both by c-Jun in vivo binding to HTR1a promoter as shown by ChIP experiments as
well as stronger activation of the C allele promoter by c-Jun using luciferase reporter
assays. Considering the interaction of activating and inhibitory TFs in eukaryotic gene
transcription, we preferentially examined effects of the transcriptional repressor Hes5
using our own bioinformatic TFBS prediction and in vitro luciferase reporter assays.
Both transcriptional regulators Hes5 and c-Jun have interfering effects on the HTR1a
promoter. c-Jun reverses the repression of Hes5 in both HTR1a promoter variants. In
particular in the HTR1a C variant this effect is substantially stronger as compared to
the HTR1a G variant.
Experimental evidence points toward an upregulation of c-Jun at early timepoints in
the lithium-pilocarpine model to induce SE in mature brain of rats, which returned to
basal level 24 hours after treatment (Han et al., 2009). Either increased stimulating
efficacy of c-Jun or reduced inhibitory effects of Hes5 on the C variant may play a
role here. With respect to investigations of respective effects of those repressors and
activators in migraine and depression, our approach reaches certain limitations. Con-
cerning the lack of availability of respective brain tissue samples, it generally needs to
be considered that the expression of particularly repressing and activating transcription
factors may be dynamic in time dimensions and also in different anatomical brain re-
gions. Respective changes may, however, be well extrapolated from animal models and
be analyzed complementary to data obtained from human biopsy brain tissue. The ex-
pression levels and dynamics of repressing and activating TFs on allelic SNP variants in
gene promoters with different binding affinities contribute a high level of complexity to
gene promoter control in brain tissue of individual humans. In contrast to the dynamic
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transcriptional changes in brain tissue, genetic variability provides a rather stable trait
of individuals to be correlated to clinical aspects of patients. These aspects may be
considered when correlating allelic variants and gene expression to clinical parameters.
6.4 Clinico-genetic correlations
Our data show allele-specific mRNA expression of genes involved in GABA-ergic or
serotoninergic homeostasis. It can be derived from multiple studies that external fac-
tors may influence gene expression in epilepsy. As demonstrated by Wang et al. or by
Christensen et al., antiepileptic drugs such as lamotrigine or levetiracetame have ef-
fects on respective gene expression (Wang et al., 2002; Christensen et al., 2010). Other
clinical parameters such as pathology (Teocchi et al., 2013) or age (Liao et al., 2010)
are also associated with potential gene expression changes.
With respect to previously studied associations of gene expression and distinct SNP
genotypes with comorbidities and clinical parameters, we analyzed clinical data for
gender, age at seizure onset, number of seizures per month, age at epileptic surgery,
pathological pattern, post operative outcome according to Engel classification, inci-
dence of depression disorder and antiepileptic and antidepressant drug therapy for
TLE patients in our collective (section 3.1 Supplemental Table 2, section 4.1 Supple-
mental Table 1 and section 5.1 Supplemental Table 1).
Considering that the evaluation of clinical data partially relies on subjective patient
information, patient samples under study are somewhat heterogeneously characterized.
We performed comprehensive covariance analysis of clinical, neuropathological patterns
and pharmacotherapy data of our patients.
Neither therapeutic variables including antiepileptic and antidepressant drugs nor clin-
ical parameters such as age at onset of epilepsy, gender and age at epilepsy surgery
reveal significant effects on gene expression of both ALDH5A1 and GABRB3 (section
3.1 Supplemental Table 4 and 5). The same holds true in covariance analyses between
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HTR1a expression and clinical parameters. None of the investigated variables indicate
a significant impact on HTR1a expression as shown in section 4 Supplemental Table 3
and 4. Our data also showed no significant association of any particular SNP genotypes
with the individual parameters investigated.
Our data do not argue in favor of an effect of clinical and therapeutical variables on
gene expression nor SNP genotypes in human surgical brain tissue of TLE patients.
The presented evidence thus emphasizes the impact of the SNP rs1883415, rs4906902
as well as rs6295 to affect corresponding gene expression in human surgical brain tissue
of TLE patients independent of covariance of clinical variables under study.
6.5 Correlation of molecular pathological parameters to seizure
frequency
The most compromizing clinical feature of chronic epilepsies are certainly seizure at-
tacks in affected patients. It represents an important but also very challenging aspect
to obtain reliable data on seizure frequency in epileptic patients obviously not being
permanently monitored in a clinical context. Nevertheless, data obtained on seizure
frequency over a time course of e.g. several months before epilepsy surgery represents
a highly valuable parameter to be correlated to pathological aspects in surgical brain
tissue samples.
In this context, multiple studies confirmed the link between seizures and inflammatory
molecules (Vezzani et al., 2000; Maroso et al., 2011). Microglial and astrocytic cells
are activated by seizures to modify inflammatory processes such as upregulation of
genes associated with immune and inflammatory responses including chemokines and
cytokines (Aronica and Gorter, 2007; Wetherington et al., 2008; Ravizza et al., 2008).
Here, we observed a significant correlation of gene expression of inflammatory media-
tors and seizure frequency in human surgical brain tissue of TLE patients. Abundant
TLR4 expression significantly correlates with high seizure frequency. The potential
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role of TLR4 as regulator in episodic brain disorders including epilepsy is supported
by TLR4 protein expression in neurons and astrocytes in epileptic tissue as well as the
significant correlation of TLR4 mRNA expression and seizure activity. This finding
in human brain tissue is in a good agreement to data from animal models showing an
epileptogenic affect of TLR4 (Maroso et al., 2010). Our present data may nevertheless
add an important aspect to the existing knowledge on TLR4 in the context of TLE,
i.e. the substantially increased expression in brain tissue that still shows a particular
high propensity for the generation of epileptic seizures even at very advanced stages
of the disease. Respective data may be rather valuable in order to translate poten-
tial antiepileptic therapies targeted to TLR4 into the context of chronic human focal
epilepsies.
In contrast to TLR4, ATF-3, inducible by stress-stimuli such as seizures (Chen et al.,
1996; Thompson et al., 2009), is expressed at only low level in patients suffering from
high seizure frequency. In accordance to the role of ATF-3 as neuronal marker of nerve
injury in the nervous system (Tsujino et al., 2000), we present ATF-3 accumulation
in neuronal components of human epileptic hippocampal tissue. Considering seizure
frequency, TLR4 and ATF-3 are reciprocally expressed and these dynamics may be
in line with a role of ATF-3 as negative regulator of TLR4 (Gilchrist et al., 2006;
Suganami et al., 2009).
Interestingly, the human-specific chemokine IL8 in our respective study exhibits strongest
correlation of seizure frequency and mRNA expression. We found IL8 protein expres-
sion in microglia and reactive astrocytes as also demonstrated in studies of Ehrlich
et al. and Hesselgesser et al. in epileptic tissue derived from pharmacoresistant TLE
patients (Ehrlich et al., 1998; Hesselgesser and Horuk, 1999). Microglial cells and also
astrocytes are present at early stages after epileptogenic insults as well as still activated
at chronic stages of focal epilepsies. The fact that with IL-8 a molecule shows a strong
correlation of expression and seizure frequency, underlines the relevance of respective
study approaches to human epileptic tissue. The access to such tissue samples allows
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the characterization of molecules, that exhibit a particular abundance in epileptic foci
with seizure activity. The fact that IL-8 is a human specific gene makes it obviously
impossible to carry out analyses of this important inflammatory factor in rodent mod-
els. However, studies in human tissue samples are certainly restricted to chronic stages
of the disease. Whether IL-8 is also a potential antiepileptogenic target can not be
accessed in human tissue samples. Therefore the development of humanized transgenic
mice may be considered in the future.
Another aspect of inflammation in epileptic tissue relates to mechanisms by which
hyperexcitability is mediated. Recent data point to a role for modulation of neuro-
transmission. Hu et al. report on contribution of inflammation to hyperexcitability
by inhibiting astrocytic glutamate reuptake (Hu et al., 2000). Viviani et al. show in-
flammatory mediators reducing GABA-mediated chloride currents or GABAA receptor
expression at neuronal membranes in order to anticipate reduction of GABA-mediated
inhibition in inflamed brain tissue (Viviani et al., 2007).
The publications, on which the present thesis is based, provide novel insights in the
relevance of dynamic expression of inflammatory factors and neurotransmission-related
molecules in epileptic tissue.
The potential of extrapolating such approaches on gene expression and corresponding
promoter regulation in a certain disease context onto a genome wide scale has become
available only recently.
7 Outlook
Considering the high complexity of the brain and neurological disorders including
epilepsy, depression and migraine, comprehensive molecular genetic approaches may
be excellently suited to understand better multilayered gene regulation processes in
human diseased brain tissue. Within the framework of this thesis we have generated
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data on SNPs, transcript abundance and promoter methylation on a genome wide level
from human biopsy epileptic tissue, which now forms the basis for further comprehen-
sive analyses.
Identification of expression quantitative trait loci (eQTL) as well as methylation quan-
titative trait loci (mQTL) will provide intriguing insights in the relevance of both cis
and trans effects of SNPs and methylation on gene expression in the human brain.
Ultimately, resulting data sets will foster the identification of gene networks involved
in multifactorial brain disease pathogenesis.
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